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Abstract 
ABSTRACT 
Joonas Lehto 
RISK FACTORS AND PROGNOSIS OF POSTPERICARDIOTOMY SYN-
DROME 
University of Turku, Faculty of Medicine, Department of Cardiology and Cardio-
vascular Medicine, Doctoral Programme in Clinical Research 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland, 2019 
Postpericardiotomy syndrome (PPS) is a common complication after cardiac sur-
gery. In most cases it develops within two to three weeks after the surgery and the 
typical symptoms include dyspnea, chest pain, and fever. An immunological 
mechanism is suspected as the cause of the disease. The disease process is usually 
self-limiting. Even though PPS occasionally requires invasive interventions, the 
prognosis of the disease is considered to be benign. This thesis investigated the 
incidence of clinically significant PPS, the risk factors for the disease, and the ef-
fect of operation type on the occurrence of the disease. Furthermore, the mortality 
of PPS patients was investigated. 
The results suggest that although the course of PPS is mostly benign, PPS requiring 
invasive interventions is associated with increased mortality. The syndrome had 
no significant impact on the occurrence of atrial fibrillation, cerebrovascular 
events, or bleeding episodes. The results also demonstrate that the incidence of 
clinically significant PPS is markedly lower compared to the diagnoses included 
in previous studies concerning the medical treatment of the disease. The use of red 
blood cell units, female sex, and younger age were identified as predisposing fac-
tors for PPS. Valve procedures and especially aortic procedures represented higher 
occurrence of the disease when compared to coronary artery bypass surgery. More-
over, PPS was less common in patients with diabetes.  
The results demonstrate that the majority of the PPS diagnoses included in recent 
studies are clinically irrelevant. The knowledge concerning the predisposing fac-
tors, such as younger age, female sex, and specific operation types, may be useful 
for the targeting of prophylactic methods. In contrast with the previous conception, 
PPS requiring the evacuation of pericardial or pleural effusion is associated with 
higher mortality. The results suggest that PPS patients requiring invasive interven-
tions are in the need of more intensive follow-up and treatment.   
Keywords: postpericardiotomy syndrome, risk factors, mortality, adverse events, 
epidemiology, cardiac surgery, pericardium
Tiivistelmä 
TIIVISTELMÄ 
Joonas Lehto  
POSTPERIKARDIOTOMIAOIREYHTYMÄN RISKIREKIJÄT JA EN-
NUSTE 
Turun yliopisto, Lääketieteellinen tiedekunta, Kardiologia ja kardiovaskulaarilää-
ketiede, Turun kliininen tohtoriohjelma 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland, 2019 
Postperikardiotomiaoireyhtymä (PPS) on yleinen sydänleikkauksen jälkeinen 
komplikaatio. Taudin tyypilliseen oireistoon kuuluu kahdesta kolmeen viikkoa sy-
dänleikkauksen jälkeen ilmaantuva hengenahdistus, rintakipu ja lämpöily. Taudin 
aiheuttajaksi epäillään immunologista mekanismia. Tautiprosessi rajoittuu yleensä 
itsestään. Vaikka PPS:n hoito vaatii joissain tapauksissa kajoavia hoitotoimenpi-
teitä, on sen ennustetta pidetty hyvänlaatuisena. Tässä väitöskirjassa tutkittiin klii-
nisesti merkittävän PPS:n ilmaantuvuutta ja riskitekijöitä sekä leikkaustyypin vai-
kutusta taudin ilmaantuvuuteen. Lisäksi tutkittiin PPS:n vaikutusta potilaiden en-
nusteeseen. 
Tämä tutkimus osoittaa, että vaikka PPS:n ennuste on pääosin hyvänlaatuinen, ka-
joavaa hoitoa vaativa PPS on yhteydessä lisääntyneeseen kuolleisuuteen. Oireyh-
tymä ei ollut merkittävästi yhteydessä eteisvärinän, aivotapahtumien tai vuotota-
pahtumien ilmaantuvuuteen. Tulokset osoittavat myös, että kliinisesti merkittävän 
PPS:n määrä on selvästi pienempi kuin taudin määrä viimeaikaisissa PPS:n lääke-
hoitoa koskevissa tutkimuksissa. Verituotteiden käytön, naissukupuolen ja nuo-
remman iän todettiin altistavan taudin kehittymiselle. Leikkaustyypeistä läppäleik-
kaukset ja erityisesti aortan toimenpiteet olivat yhteydessä taudin lisääntyneeseen 
ilmaantuvuuteen sepelvaltimoiden ohitusleikkaukseen verrattuna. Lisäksi diabe-
teksen todettiin merkittävästi vähentävän taudin ilmaantuvuutta.  
Tulokset osoittavat, että valtaosa viimeaikaisten tutkimusten PPS-diagnooseista on 
kliinisesti merkityksettömiä. Tieto taudille altistavista tekijöistä, kuten nuorempi 
ikä, naissukupuoli ja tietyt leikkaustyypit, voi olla hyödyllistä, kun valitaan koh-
teita taudin ennaltaehkäiseville toimille. Aiemmasta käsityksestä poiketen PPS on 
yhteydessä lisääntyneeseen kuolleisuuteen. Vaikka löydöksen syitä on tutkittava 
vielä lisää, tulosten perusteella kajoavaa hoitoa vaativat PPS-potilaat ovat kuole-
manvaarassa ja tarvitsevat siksi nykyistä intensiivisempää hoitoa ja seurantaa. 
Avainsanat: postperikardiotomiaoireyhtymä, riskitekijät, kuolleisuus, haittavaiku-
tukset, epidemiologia, sydänkirurgia, perikardium
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1 INTRODUCTION 
Postpericardiotomy syndrome (PPS) is a common complication after cardiac sur-
gery. The syndrome is a subgroup of post-cardiac injury syndromes (PCIS) to-
gether with postmyocardial infarction syndrome (Dressler’s syndrome) and post-
traumatic pericarditis (Imazio et al., 2013d). The typical clinical picture consists 
of pleuritic chest pain and fever appearing few days to several weeks after cardiac 
surgery (Imazio, 2012). Even though the syndrome was first described in the 1950s 
(Janton et al., 1952; Soloff et al., 1953), the etiology of the syndrome has remained 
obscure. Currently, PPS is presumed to be an immune-mediated process initiated 
by pericardial and/or pleural damage and pericardial bleeding but the role of viral 
infections and other possible acquired factors is not well understood (Imazio, 
2012).  
In previous studies, the incidence of PPS has varied between 10 and 40% (Imazio 
et al., 2013d). In recent prospective studies the reported incidences have been be-
tween 21 and 29 % (Imazio et al., 2010, 2014c). The large variability between the 
studies has evolved mostly from the differences in diagnostic criteria, patient pop-
ulations, and procedure types (Imazio, 2012; van Osch et al., 2017b). Standardized 
criteria for the syndrome were first described in 2015 in the European Society of 
Cardiology Guidelines with an objective to reduce the variability between studies 
(Adler et al., 2015). The recommended criteria have, however, already received 
criticism due to their weak correlation with the clinical picture, overflowing sen-
sitivity, and non-specificity (van Osch et al., 2017b).  
The current guidelines recommend the use of non-steroidal anti-inflammatory 
drugs (NSAIDs) combined with colchicine in more severe cases in the treatment 
of the syndrome (Adler et al., 2015). Even though PPS occasionally requires inva-
sive interventions, such as pericardial or pleural draining, as well as longer hospital 
stays and readmissions (Imazio et al., 2011b), the prognosis of the syndrome is 
considered to be benign (Bucekova et al., 2012; Imazio, 2012; Imazio et al., 
2013d). However, this perception is mainly based on clinical experience rather 
than appropriate epidemiological studies concentrating on the long-term prognosis 
of the syndrome. 
This thesis focuses on the occurrence, risk factors, and prognosis of PPS requiring 
medical attention. The recent prospective studies have included PPS patients with 
a broad spectrum resulting in a high apparent incidence of the syndrome. However, 
the clinical relevance of the diagnoses is uncertain. Several approaches are used to 
evaluate the aforementioned issues which are crucial to the assessment of appro-
priate clinical approach to the syndrome in the “real world” practice.
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2 REVIEW OF LITERATURE 
2.1 Cardiovascular surgery 
The term “cardiovascular surgery” covers all open-heart procedures, including 
procedures for congenital heart disease, ischemic heart disease, valvular heart dis-
ease, aortic disease, atrial and ventricular arrhythmia, myotomies, the installation 
of mechanical circulatory support devices, and cardiac transplantations. The fol-
lowing sections detail the four cardiac procedure types included in the present in-
vestigation. 
2.1.1 Coronary artery bypass graft surgery 
Typical anesthesia for cardiac surgery includes inhalational anesthetics (sevoflu-
rane or desflurane) in conjunction with muscle relaxants and modest dosage of 
opioids for analgesia. Additionally, the maintenance of anesthesia typically in-
cludes intravenous antibiotics with gram-positive pathogen coverage (typically ce-
furoxime) 30–60 minutes before the skin incision, intraoperative blood glucose 
control with insulin, acid-base management, heparinization for cardiopulmonary 
bypass (CPB), hypothermia, hemodynamic adjustment after the separation from 
CPB (vasopressors, vasodilators, catecholaminergic agents, phosphodiesterase in-
hibitors), and possible mechanical support devices (e.g., an intra-aortic balloon 
pump) (Sellke et al., 2010).  
The progress of cardiac surgery procedures follow a fairly uniform scheme as de-
scribed in textbooks (Sellke et al., 2010). The most widely used exposure is the 
midline sternotomy with the skin incision made from the manubrium of the ster-
num to the xiphoid process. After a slight mobilization of the subcutaneous fat the 
sternum is divided with a saw. Meticulous hemostasis is ensured at all stages. A 
pericardial incision is performed in the extent needed according to the procedure 
type. Coronary artery bypass graft (CABG) is performed on CPB in the majority 
of cases. CPB is most often established with ascending aortic or arch cannulation 
and right atrial venous cannula drainage. The extracorporeal circulation can be ex-
ecuted by conventional extracorporeal circulation (CECC) or minimal invasive ex-
tracorporeal circulation (MiECC). MiECC consist of a centrifugal pump–driven, 
closed and minimized circuit without open venous reservoir, whereas CECC ex-
ploits conventional roller pumps or centrifugal pumps and open venous reservoir 
(Ellam et al., 2019). The aorta is cross-clamped, and venting (i.e., de-airing and 
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suction of blood) is performed via the proximal ascending aorta by using the ante-
grade cardioplegia delivery catheter. After the first dose of cardioplegia has been 
delivered, the construction of distal coronary anastomoses begins. In the vast ma-
jority of cases the LAD is grafted with the LITA while additional anastomoses are 
grafted with saphenous vein or radial artery grafts and the right internal thoracic 
artery (RITA). The epicardium is incised over the intended area of the coronary 
artery, the anterior wall of the artery is opened longitudinally, and the anastomoses 
are attached using 7-0 or 8-0 polypropylene suture. Most proximal anastomoses 
are made on the ascending aorta, and alternative sites such as end-to-side anasto-
moses to the LITA can be used as needed or convenient.  
During the weaning from CPB, the patient is slowly rewarmed, the aortic cross-
clamp is removed, atrial and ventricular epicardial pacing wires are affixed to the 
heart when necessary, and the heart rhythm and rate are optimized using cardio-
version or pacing as necessary. The venous cannula is removed, protamine is ad-
ministered, chest tubes are inserted in the posterior pericardium, the anterior me-
diastinum, and each pleural cavity entered, and aortic cannula is removed. The 
pericardium is sometimes, mainly depending on local custom, partially reapproxi-
mated over the anterior left ventricle, and the sternum and skin incision are closed.  
Alternatively, coronary surgery can be performed “off-pump” without CPB with a 
beating heart (Trapp et al., 1975). Off-pump coronary surgery is performed now-
adays in approximately one sixth of the cases (Bakaeen et al., 2014). Surgical ex-
posures are for the most part similar to “on-pump” surgery, but the anastomotic 
epicardial sites are stabilized and the heart is positioned with suction stabilizers 
(Borst et al., 1996) and gauze harnesses and no aortic or venous cannulation is 
employed. Myocardial perfusion can be maintained using temporary intracoronary 
shunts. 
2.1.2 Surgical aortic valve replacement 
Surgical aortic valve replacement (SAVR) is most commonly performed to treat 
aortic valve stenosis, but it is also indicated in other pathologies such as aortic 
regurgitation, combined stenosis and regurgitation, and infective endocarditis 
(Baumgartner et al., 2017). The procedure is typically performed via median ster-
notomy similar to the CABG procedure as specified above. Cannulations are sim-
ilar to those used in CABG, but the left ventricle is often directly vented via a 
cannula inserted through the right upper pulmonary vein and cardioplegia can be 
administered retrogradely through coronary venous cannulation via the coronary 
sinus. Once the heart is arrested, the aortic valve may be approached through a 
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transverse or oblique aortotomy. The incision is typically carried out into the non-
coronary sinus if root enlargement is contemplated. The valve is lifted with the 
help of traction sutures to improve visualization, if necessary. The native valve is 
removed using scissors and rongeurs.  
Possible valve replacements include a bioprosthesis, a mechanical valve, some-
times a homograft, and in rare cases in children and young adults an autograft 
(Ross procedure). Most commonly, the valve is implanted using pledgeted hori-
zontal mattress sutures of braided polyester. Aortotomy closure is then accom-
plished with running polypropylene suture. The weaning from CPB is accom-
plished similarly as specified above.  
2.1.3 Mitral valve repair and replacement 
Mitral valve surgery is most commonly performed due to mitral valve regurgita-
tion, in addition to the nowadays relatively rare cases of mitral stenosis 
(Baumgartner et al., 2017). Mitral valve procedures are also typically approached 
via median sternotomy. The procedure is classically performed with cardioplegic 
arrest, but in a selected group of patients, alternative techniques, such as beating 
heart and ventricular fibrillatory arrest, are available. The three most commonly 
used approaches for the exposition of the mitral valve include: the interatrial ap-
proach through Sondergaard’s groove, the horizontal biatrial trans-septal ap-
proach, and the superior biatrial trans-septal approach. The most commonly used 
approach is the interatrial approach through Sondergaard’s groove which includes 
the incision of the interatrial groove and the dissection and dividing of the two atria 
up to the fossa ovalis. The roof of the left atrium is then opened close to the mitral 
valve.  
The repair of the mitral valve is preferred over replacement with a prosthesis in 
most indications (Baumgartner et al., 2017). Mitral valve repair techniques are nu-
merous but almost always include remodeling ring annuloplasty complemented by 
techniques aimed at re-establishing leaflet function such as quadrangular resection 
of a prolapsed posterior leaflet area, triangular resection of the prolapsed anterior 
leaflet area, choral transfer, chordal transposition, chordal shortening, artificial 
chordoplasty, and papillary muscle sliding plasty and shortening. In patients for 
whom mitral valve repair is not suitable, mitral valve replacement (MVR) with 
either a bioprosthesis or a mechanical prosthesis is performed. The anterior leaflet 
is detached, and the posterior leaflet is typically left intact. The mitral prosthesis is 
inserted most commonly using horizontal mattress sutures. After the closure of the 
atrium, the weaning from CPB is started. 
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2.1.4 Ascending aortic surgery 
Ascending aortic surgery is typically performed to treat the enlargement of the 
aortic root or ascending aorta, or, emergently, to treat aortic dissection or rupture 
(Pan et al., 2018). Procedures are performed via median sternotomy, and they re-
quire an extensive preparation of the pericardial reflection. The CPB is established 
by arterial cannulation of the transverse aortic arch, right axillary artery or femoral 
artery, and venous cannulation through the right atrium or femoral vein. Deep or 
moderate hypothermia is employed to protect from end-organ ischemia as a brief 
circulatory arrest is often necessary to complete the anastomoses to the arch or 
supra-aortic vessels. The ascending aorta is replaced using a tubular vascular graft. 
Patients with aortic valve disease not amenable to repair are treated by AVR and 
supracoronary replacement of the ascending aorta. If only the noncoronary aortic 
sinus is dilated, AVR with a graft extension into the noncoronary sinus can be 
performed. Composite replacement of the aortic valve and ascending aorta with 
the reimplantation of the coronary arteries is performed if two or more aortic si-
nuses are dilated. When the aortic valve cusps are not calcified, aortic valve spar-
ing techniques such as the David reimplantation (David et al., 1992) or Yacoub 
remodeling procedure (Yacoub et al., 1983) can be performed. After all the sutures 
are sealed, the patient is slowly rewarmed and the weaning from CRP is accom-
plished as specified above. 
2.2 Pericardium 
The pericardium consists of visceral and parietal components. The visceral com-
ponent, layering the surface of the heart, is a monolayer of mesothelial cells adher-
ing firmly to the epicardium via fibrous tissue containing elastic fibers. The parie-
tal layer consists of dense collagen bundles with interspersed elastic fibers that 
form a tough sac enveloping the heart surfaced with a serosal layer of mesothelial 
cells. Outside the fibrous pericardium is a variable amount of adipose tissue lay-
ered with mesothelial cells (Cremer et al., 2016; Hoit, 2017). The parietal compo-
nent of pericardium is continuous with the visceral pericardium tethering around 
the origin of the great vessels. Between the two serosal layers encloses the pericar-
dial space that normally contains up to 50 ml of plasma ultrafiltrate (Spodick, 
1992; Hoit, 2017). Besides the roots of the great vessels, the parietal component is 
attached to diaphragm, sternum, and vertebral bodies by ligamentous attachments 
neutralizing the effects of respiration and change of body position and preventing 
the torsion and displacement of the heart (Troughton et al., 2004). The arterial 
supply of the pericardium comes from small aortic branches in the posterior part 
and from internal thoracic arteries in the superior, lateral, and inferior proportions 
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of the parietal pericardium. The anterior and posterior parietal pericardium as well 
as visceral pericardium all contain lymphatics draining to anatomically corre-
sponding mediastinal nodes (Spodick, 1992).  
The pericardium is not an essential structure, although it has many advantageous 
functions. The pericardial fluid reduces friction, equalizes forces directed to the 
heart (i.e., gravitation and accelerations) hence minimizing the pressure changes 
in the cardiac muscle, and works as a mechanical barrier to infection. The fibrous 
layer limits cardiac distention and maintains the pressure-volume relations of the 
cardiac chambers. Also, the mesothelial layer is metabolically active modulating 
numerous immunologic, vasomotor, and fibrinolytic functions and modulates the 
sympathetic neurotransmission and contractility (Spodick, 1992; Hoit, 2017). 
Pericardial heart diseases include infectious (viral, bacterial, fungal, and parasitic) 
and non-infectious pericardial diseases (autoimmune, neoplastic, metabolic, trau-
matic and iatrogenic, drug-related, congenital, and other diseases, including aortic 
dissection and amyloidosis), in addition to the complications of pericarditis, in-
cluding constriction and acute tamponade (Adler et al., 2015). The inflammatory 
states damage the visceral pericardium, also interfering with epicardial venous and 
lymphatic flow, leading to loss of interstitial fluid from the myocardium to the 
pericardial space (Spodick, 1983). This leads to pericardial effusion accompanied 
with the accumulation of inflammatory cells and increased fibrin production (Hoit, 
2017). Rapid increases in the volume can cause tamponade even if the pericardial 
effusion was relatively small. However, slowly developing effusions may not pro-
duce tamponade even in large volume (Imazio et al., 2013a). The healing process 
may result in pericardial adhesions between the visceral and parietal layers and 
later calcification (Hoit, 2017).  
2.3 Postpericardiotomy syndrome 
2.3.1 Epidemiology of PPS 
The first descriptions of PPS date back to 1950s, shortly after the establishment of 
the first surgical cardiac valve procedures, when Janton and colleagues reported 
the results of their first 100 consecutive commissurotomies for mitral stenosis 
(Janton et al., 1952). The authors observed unpredictable pleuropericardial pain 
unresponsive to salicylates, antibiotics, and ordinary doses of narcotics in about 30 
percent of the patients. The symptoms occurred typically during the second post-
operative week. The episodes were considered to be possible manifestations of 
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smoldering rheumatic activity, even though only one sixth of all patients had mi-
croscopic evidence of active rheumatic infection in the left auricular appendage. 
Soloff and colleagues investigated the syndrome further and observed an incidence 
of 24% after consecutive mitral commissurotomies (Soloff et al., 1953). Because 
of the misunderstood causality, the syndrome was named “postcommissurotomy 
syndrome” until 1958, when an identical state was detected following cardiac sur-
gery in patients without rheumatic heart disease (Ito et al., 1958). The syndrome 
was only observed when the pericardial cavity was entered, and therefore it was 
renamed “postpericardiotomy syndrome”.  
The reported incidences of the syndrome have varied largely. During the first years 
after the discovery of the syndrome the incidence varied from 4% to 63% after 
mitral commissurotomy with an average of 17% (Janton et al., 1952; Soloff et al., 
1953; Wood, 1954; January et al., 1954; Julian et al., 1954; Fell et al., 1955; 
Dresdale et al., 1956; Papp et al., 1956; Hall et al., 1958; Likoff et al., 1958; Lisan 
et al., 1959; Bain et al., 1961). Besides the differences in diagnostic criteria, which 
were not reported in most of the studies, this exceptionally large variety illustrates 
the lack of effective differential diagnostic equipment, especially the heart echo-
cardiography. After the inclusion of different procedure types, the syndrome was 
detected in 27–31% of patients (Drusin et al., 1965; Engle et al., 1980). Studies 
requiring good response to steroid therapy for the diagnosis reported incidences of 
6–7% (Louhija et al., 1971; Ikäheimo et al., 1988). 
Engle concluded that the incidence of PPS, according to their quite comprehensive 
prospective studies, was 27% in children and 18% in adults aged 21 years or older 
(Engle, 1982). After the age of 70 years the incidence decreased to 10%. Further-
more, patients aged under 2 years presented very few cases of PPS (3.5%) and 
infants under the age of six months did not seem to present with the syndrome at 
all. Later, consistent with the aforementioned study, a large prospective epidemi-
ological study by Miller et al. observed an incidence of 24% in patients under 54 
years, 18% in patients 55–64 years, and 11% in patients over 65 years after careful 
differential diagnostic procedures (Miller et al., 1988). 
In the major PPS studies during the last decades, the reported incidences have been 
the following: 10–28% in children (Wilson et al., 1994; Mott et al., 2001; Webber 
et al., 2001; Heching et al., 2015; Rabinowitz et al., 2018) and 15–21% in adults 
(Horneffer et al., 1990; Imazio et al., 2010; Bunge et al., 2014) with a median of 
16% in adult patients (van Osch et al., 2017b). In the recent COPPS-2 trial (Imazio 
et al., 2014c), the incidence in adult patients was as high as 29% in elderly patients, 
although the time limit of fever was abandoned resulting in a markedly higher oc-
currence during the first postoperative days compared to the COPPS trial (Imazio 
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et al., 2010). The reported incidences of PPS and details of major PPS studies are 
presented in Figure 1.  
 
Figure 1. Reported incidences of PPS and study specifications in major previous studies. Artwork 
by Joonas Lehto. ASD: atrial septal defect; CABG: coronary artery bypass grafting; PPS: post-
pericardiotomy syndrome; VSD: ventricular septal defect. 
After pacemaker implantation the incidence of PPS has been reported to be 1.8%, 
with a higher risk after the insertion of epicardial leads (2.5%) compared to trans-
venous leads (1.0%) (Zeltser et al., 2004), although markedly lower incidences 
(<0.2%) have also been reported (Gatzoulis et al., 2014). It appears that the inci-
dence is roughly 2–5% after the implantation of active-fixation leads and notably 
lower after passive-fixation leads (Sedaghat-Hamedani et al., 2014). After radiof-
requency ablation complicated by cardiac perforation, the incidence is 28.6%, in 
other words similar to that after cardiac procedures (Liu et al., 2013). 
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2.3.2 Clinical features of PPS 
PPS typically occurs within one months after the surgery, and an initial onset after 
six months is rare (Lisan et al., 1959; McGuinness et al., 1962; Ikäheimo et al., 
1979; Nishimura et al., 1983; Imazio et al., 2011b; Alraies et al., 2014; Gabaldo 
et al., 2019). In children, the onset is slightly earlier, typically within 1 to 2 weeks 
(Engle et al., 1980; Mott et al., 2001; Heching et al., 2015). The median duration 
of the syndrome is 2–3 weeks (Drusin et al., 1965; Nishimura et al., 1983; Heching 
et al., 2015), and possible relapses tend to occur within 2–11 weeks after the initial 
onset (McGuinness et al., 1962).  
The most characteristic symptom of PPS is pleuritic or pericarditic chest pain, re-
ferring to a stabbing pain often radiating to precordial region, neck, back, shoul-
ders, arms, lower chest, and abdomen, made worse by coughing, deep breathing, 
swallowing, or any movement, and in severe cases leading to a fast and shallow 
respiration easily confused with the dyspnea of congestive heart failure (Papp et 
al., 1956; Lisan et al., 1959; Gore, 1960; Uricchio, 1963; Maisch et al., 1979; 
Nishimura et al., 1983). The reported incidences of the symptom have varied 
largely, but according to a recent prospective study, pleuritic chest pain occurs in 
over a half of the PPS episodes (Imazio et al., 2011b). An intermittent, low grade 
fever is another common feature of PPS, and it occurs in approximately a half of 
the PPS cases (Imazio et al., 2011b; Gabaldo et al., 2019). The fever is usually the 
first manifestation. It may merge with the early postoperative temperature eleva-
tions so that the patient has a prolonged febrile course, but more often the fever 
recurs as a delayed reaction after a distinct afebrile period (Engle et al., 1961). 
Another characteristic clinical finding is pericardial friction rub detected in the 
heart auscultation. The reported incidences of the friction rub have varied tremen-
dously. According to recent studies it is detected in 20 to 30% of patients (Imazio 
et al., 2011b; Alraies et al., 2014), although it has been suggested that it could 
probably be heard at some time in all patients but due to the transient nature a serial 
auscultation strategy is necessary (Engle et al., 1961). The start of medical treat-
ment, especially corticosteroids, offers a prompt relief of symptoms, typically 
within 24 to 48 hours (Kaminsky et al., 1982). 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are elevated in 
most PPS patients (Soloff et al., 1953; Elster et al., 1954; Fell et al., 1955; Ito et 
al., 1958; Tabatznik et al., 1961; Urschel et al., 1976; Nishimura et al., 1983; 
Alraies et al., 2014; Gabaldo et al., 2019), although their specificity is poor during 
the first weeks after cardiac surgery (Bartels et al., 1994; Köhler et al., 2003). 
Other typical laboratory findings include neutrophilic leukocytosis (Soloff et al., 
1953; Ito et al., 1958; Tabatznik et al., 1961; Uricchio, 1963; Urschel et al., 1976; 
Maisch et al., 1979). If pericardiocentesis is performed, the pericardial effusion is 
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clear, straw-colored fluid or serosanguineous fluid and sterile on culture (Papp et 
al., 1956; Ito et al., 1958; Engle et al., 1961; Tabatznik et al., 1961; Bortolotti et 
al., 1981; Ofori-Krakye et al., 1981; Meyers et al., 1997; Karatolios et al., 2013). 
The fluid is exudate containing high counts of lymphocytes and red blood cells and 
relatively high counts of granulocytes (Ofori-Krakye et al., 1981; Meyers et al., 
1997; Karatolios et al., 2013). The specifications of pleural effusions are similar 
to the ones in pericardial fluid (Papp et al., 1956; Bielsa et al., 2016). 
The thoracic X-ray reveals unilateral (usually left) or bilateral pleural effusion in 
most of the patients with PPS (Elster et al., 1954; Ito et al., 1958; McGuinness et 
al., 1962; Maisch et al., 1979; Nishimura et al., 1983; Imazio et al., 2011b; Bielsa 
et al., 2016; Gabaldo et al., 2019). The separation of the pleuritic effusions from 
the normal surgery-related effusions is however complicated, as >80% of patients 
have at least minor effusions during the postoperative period (Bunge et al., 2014). 
ECG findings, including low voltage of the QRS, T-wave inversion, or ST-seg-
ment elevation or depression, can be detected in approximately half of the patients. 
(Elster et al., 1954; Papp et al., 1956; Johnson, 1959; Tabatznik et al., 1961; 
Uricchio, 1963; Nishimura et al., 1983). However, these findings as well seem to 
be relatively nonspecific and thus only marginally helpful (Miller et al., 1988), and 
ECG changes suggestive of pericarditis appear only in <¼ of cases (Imazio et al., 
2011b). 
The pericardial effusion can often be detected on chest x-ray as an enlargement of 
the cardiac silhouette. However, it is often difficult to tell whether this enlargement 
is cardiac or pericardial or both (Engle et al., 1961; Kaminsky et al., 1982; 
Nishimura et al., 1983). According to recent studies, pericardial effusion can be 
detected as often as in 89% of the episodes (Imazio et al., 2011b; Alraies et al., 
2014). The effusion is typically mild (<10 mm), and moderate (10–20 mm) and 
large (>20 mm) effusions are detected in 13% and 4%, respectively (Imazio et al., 
2011b). Most patients (>80%) have combined pleuropericardial involvement 
(Imazio et al., 2011b). The typical echocardiographic finding is presented in Fig-
ure 2. 
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Figure 2. An echocardiographic image taken in the parasternal long axis view demonstrates mod-
erate pericardial effusion in the posterior pericardium. Artwork by Joonas Lehto. 
2.3.3 Diagnostic criteria 
PPS is a diagnosis of exclusion. Since there are no specific tests with which to 
establish the diagnosis, it is made by excluding other diseases potentially produc-
ing similar symptoms. The main diagnoses to exclude are incisional pain, pneu-
monia, mediastinitis, congestive heart failure, atelectasis, bacterial endocarditis, 
sepsis, myocardial or pulmonary infarction, pulmonary embolism, and aortic dis-
section (Kirsh et al., 1970; Barnhorst, 1973). The evaluation of a patient with a 
suspected PPS includes a focused physical examination to detect pleural or peri-
cardial rubs, laboratory tests (blood count and markers of inflammation and myo-
cardial necrosis), ECG, chest X-ray, and transthoracic echocardiography to detect 
the presence, size, and hemodynamic importance of the pericardial effusion 
(Imazio et al., 2013d; Adler et al., 2015). 
Since the first description of PPS, numerous different diagnostic criteria have been 
used in research with a striking inconsistency between one another (van Osch et 
al., 2017b). Engle et al. were the first to specify the diagnostic criteria for PPS 
(Engle et al., 1974). Patients were diagnosed with PPS when there was either the 
persistence or appearance of the following combination of findings beyond the first 
postoperative week: fever not otherwise explained, together with signs of pericar-
dial reaction on physical examination and serially obtained electrocardiograms and 
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roentgenograms. At that time, the one week boundary was in general use, as it is 
usually safe to assume that symptoms occurring before the seventh day are part of 
the normal postoperative course (Lessof, 1976). In fact, fever early in the first post-
operative week is virtually universal (Livelli et al., 1978), and benign, surgery-
related pleural effusion appear in 50% of the patients without PPS during the first 
postoperative days (Kaminsky et al., 1982). Besides fever and pleural effusions, 
benign, surgery-related leukocytosis, pericardial effusion, pericardial friction rub, 
and electrographic changes of pericarditis diminish after the 1st postoperative week 
enabling the diagnosing of PPS (Engle et al., 1978). 
Table 1. Definition and diagnosis of postopericardiotomy syndrome (PPS) according to the 
ESC Guideline (Adler et al., 2015).  
In the year 2015, European Society of Cardiology (ESC) published the first guide-
line recommending diagnostic criteria for PPS which are the following: 1) fever 
without alternative causes, 2) pericarditic or pleuritic chest pain, 3) pericardial or 
pleural rubs, 4) evidence of pericardial effusion and/or 5) pleural effusion with 
elevated CRP (Table 1). Two of the criteria should be fulfilled for the diagnosis, 
and the demonstration of inflammatory activity should be essential to establish the 
diagnosis (Adler et al., 2015). Neither the a time limit for the fever often used in 
the earlier studies nor the “new or worsening” term of pericardial or pleural effu-
sion included in the review concerning the diagnostic criteria (Imazio et al., 2013c) 
were included in the criteria for a reason not specified. The criteria have been re-
cently criticized accordingly (van Osch et al., 2017b), although any sort of univer-
sal recommendations should reduce the variety of employed diagnostic criteria in 
future PPS studies. Although not included in the ESC guideline, exclusive criteria 
for children have been also proposed by Heching and colleagues (Heching et al., 
2015). 
2.3.4 Risk factors for PPS 
Numerous previous studies have evaluated the risk factors for PPS to both clarify 
the cause of the syndrome and to identify the patients with the highest risk of de-
veloping the disease. One of the few risk factors several studies have agreed upon 
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1. Fever without alternative causes 
2. Pericarditic or pleuritic chest pain 
3. Pericardial or pleural rubs 
4. Evidence of pericardial effusion 
5. Pleural effusion with elevated CRP 
At least 2 of 5 criteria should be fulfilled. 
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2015). 
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is female gender (Larson, 1957; Webber et al., 2001; Imazio et al., 2011b), alt-
hough contradicting reports have also been published (Miller et al., 1988; van Osch 
et al., 2017a). It has been suggested that this finding might reflect a different pre-
disposition to autoimmune pathogenesis, as it is known that women are more sus-
ceptible to a variety of autoimmune diseases (Voskuhl, 2011). 
Another factor most certainly influencing the occurrence of PPS is age. According 
to previous studies, the incidence of PPS decreases above the age of thirty (Drusin 
et al., 1965), is minimal in children under two years, and is the highest immediately 
after that, at the age of two years (Engle et al., 1980). The absence of the syndrome 
in infants has been hypothesized to be related to the short period of experience 
with exposure to viruses, so that these patients do not react immunologically to the 
new stress by developing PPS (Engle, 1982). Furthermore, infants under the age 
of six months did not develop PPS at all, possibly due to protection by transplacen-
tal transfer of maternal antibody and the absence of contact with people with res-
piratory or gastrointestinal infections. Engle also discussed that a certain degree of 
maturity of the immunological system might be required before the infant can 
mount the kind of autoimmune response and anti-viral reaction that can be tested 
by measurements of AHA and titers of anti-viral agents. It needs to be taken into 
consideration, however, that infants are generally unable to express themselves 
concerning chest pain and other subjective findings. The incidence of PPS seems 
to decrease steadily from early adulthood to old age, and the incidence in patients 
aged 70 years falls to 10% (Engle, 1982; Köhler et al., 2003). This may be due to 
the acquired protection over many years of exposure to viral illnesses and, on the 
contrary, less frequent recent exposure to viral infections because of the alterations 
in lifestyle. Also, with aging, possibly comes some immunosenescence, so that 
they are less capable of mounting an immune response against the intrapericardial 
trauma and possible exposure to viruses in the hospital (Engle, 1982). Negative 
results concerning the association of PPS and age has also been reported (Maisch 
et al., 1979; Imazio et al., 2011b; Jaworska-Wilczyńska et al., 2014; Heching et 
al., 2015; Sevuk et al., 2015, 2016c, 2016b; van Osch et al., 2017a), although typ-
ically in cohorts with a highly delineated age distribution. Moreover, a nonsignif-
icant trend towards higher PPS occurrence in younger patients is detectable in most 
of the studies.  
During the first decades after the description of PPS, the research payed attention 
to seasonal changes in PPS occurrence. McGuinness and colleagues found a sum-
mer peak of incidence (McGuinness et al., 1962). Drusin et al. suggested that the 
incidence of PPS was higher during the consecutive six-month period from Febru-
ary through July (Drusin et al., 1965). These findings were later confirmed in a 
large prospective epidemiological study, as summer months (May, June, and July) 
presented a significant seasonal peak the lowest incidence occurring during early 
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fall months (August, September, and October) (Miller et al., 1988). This seasonal 
peak suggested the possibility that a pre-existing virus is activated by the operation 
and produces the syndrome. The pathogenetic involvement of viruses is discussed 
below.  
A retrospective analysis by Alraies et al. assessed the predictors of PPS leading to 
procedural intervention due to the pericardial effusion or pericardial constriction 
(Alraies et al., 2014). Independent predictors of invasive interventions included 
younger age (OR 1.03, 95% CI 1.01–1.05), early onset of PPS (OR 1.03, 95% CI 
1.01–1.05), and constrictive physiology (OR 6.23, 95% CI 2.04–19.07) when com-
pared to PPS patients not requiring invasive interventions. The higher incidence 
within younger individuals is presumably related to the more aggressive immune 
response discussed above. However, the results have been challenged, as the older 
patients also received a somewhat more aggressive medical treatment for the dis-
ease (Chhabra et al., 2015). No other studies assessing the risk factors for adverse 
outcomes of PPS have been previously published. 
The type and/or extent of the procedure has also been reported to influence the 
incidence of PPS. Engle et al. found PPS occurring at a higher frequency in pro-
cedures for the tetralogy of Fallot and ventricular septal defect (VSD) accompa-
nied by some other anomaly compared those entailing less damage to the cardiac 
muscle (ASD, isolated VSD, TGA, pulmonary stenosis) (Engle et al., 1980). De 
Scheerder et al. also found that PPS was more common after valve replacement 
operation as compared to after CABG (De Scheerder et al., 1984, 1991). In an 
epidemiological setting containing only adult patients, AVR patients were at 
greater risk for PPS and mitral valve replacement patients appeared to have a re-
duced risk (Miller et al., 1988). Other procedures presented relatively high inci-
dence. The lower incidence in patients undergoing MVR remained equivocal but 
it was presumed that the underlying cause of the valvular disease may play a role. 
The number of grafts in CABG was not associated with the incidence of PPS. 
Overall, it seems that the procedure type has an impact on the occurrence of PPS, 
although it was observed already during the first years after the description of the 
syndrome that it can appear also after exploratory pericardiotomies in whom no 
further surgical procedures are attempted (Ito et al., 1958). 
Although PPS most commonly occurs after cardiac surgeries and especially fre-
quently after the most extensive procedures, numerous case reports concerning 
more unusual triggers of PPS have been previously published. A picture similar to 
PPS has followed penetrating injuries of the chest (Segal et al., 1960; Tabatznik et 
al., 1961; Loughlin et al., 1987), gunshots of the thoracic area (Tabatznik et al., 
1961; Zeft et al., 1965; Akdemir et al., 2003), nonpenetrating trauma to the chest 
(Goodkind et al., 1960; Gunnar et al., 1962; Sikes, 1963; Goldstein et al., 1965), 
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left ventricular puncture (Stewart et al., 1962; Peter et al., 1966), pulmonary em-
bolism (Jerjes-Sanchez et al., 1987), pacemaker implantation with epicardial leads 
(Dressler, 1962; Wang et al., 1983; Terada et al., 1995), transvenous pacemaker 
implantation (Kaye et al., 1975; Snow et al., 1987; Lau et al., 1992; Hargreaves et 
al., 1994; Miller et al., 1996; Bajaj et al., 1999; Spindler et al., 2001; Sasaki et al., 
2001; Turkie et al., 2005; Cevik et al., 2009; Tsai et al., 2012; Sedaghat-Hamedani 
et al., 2014; Gatzoulis et al., 2014; Salih et al., 2015; Kumar et al., 2018), coronary 
artery perforation during balloon angioplasty (Escaned et al., 1992), uncompli-
cated coronary angioplasty and stenting (Hearne et al., 2003; Setoyama et al., 
2006; Gungor et al., 2008; Park et al., 2010; Kawase et al., 2015; Gurunathan et 
al., 2016; Elbaz-Greener et al., 2017; Paiardi et al., 2017; Gavrielatos et al., 2018), 
percutaneous mitral balloon valvuloplasty (Demirtas et al., 1998), atrial radiofre-
quency ablation (Turitto et al., 1998; Wood et al., 2003; Koller et al., 2004; Tang 
et al., 2007; Zheng et al., 2007; Yukumi et al., 2015), diagnostic transdiaphrag-
matic pericardial window (King et al., 2009), thymectomy (Santos et al., 1992; 
Yukumi et al., 2012; Nishimura et al., 2019), accidental opening of the pericar-
dium during lung lobectomy (Eguchi et al., 2010), and Nuss procedure 
(Muensterer et al., 2003; Berberich et al., 2004).  
In the case reports of nonpenetrating traumas to the chest, the pericardiocentesis 
and/or thoracocentesis revealed either blood in the pleural or pericardial cavities 
during the initial trauma or serosanguineous fluid during the pleuropericarditis by 
rule. Therefore, according to these reports, the only required trigger for the syn-
drome seems to be the presence of pericardial hematoma and/or a compressing 
injury of the heart during a car accident, although laceration or contusion of the 
pericardium cannot be ruled out. Atrial or ventricular wall perforation with bleed-
ing into the pericardial sac occurring without recognition is a possible complica-
tion of transvenous pacemaker implantation, and it has been discussed to be the 
possible etiology of the relatively rare cases resulting to PPS (Sedaghat-Hamedani 
et al., 2014). This hypothesis is strengthened by the observations that only leads 
placed on the lateral or anterolateral wall seem to provoke acute pericarditis 
(Greene et al., 1994) and that active-fixation leads seem crucial for the develop-
ment of the disease (Gatzoulis et al., 2014; Sedaghat-Hamedani et al., 2014). Di-
rect irritation of the pericardium by slightly protruding electrodes might be another 
possible trigger for the inflammatory response (Wolk et al., 2013; Gatzoulis et al., 
2014; Sedaghat-Hamedani et al., 2014). Hemopericardium is also a rare but pos-
sible complication of percutaneous mitral balloon valvuloplasty (Tuzcu et al., 
1992). An unrecognized perforation of a coronary artery causing small bleeding 
into the pericardial space is a potential complication of percutaneous coronary in-
tervention (Setoyama et al., 2006; Park et al., 2010; Elbaz-Greener et al., 2017), 
although also prolonged endothelial trauma (Gungor et al., 2008) combined with 
negative remodeling due to the myocardial damage (Gavrielatos et al., 2018) has 
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been suggested to be the inducing factors. In one of the percutaneous coronary 
intervention cases, PPS required pericardiocentesis, and erythrocytes were identi-
fied in the evacuated fluid (Park et al., 2010). In the seven cases of atrial radiofre-
quency ablation, the authors suggested either the extensive transmural atrial or per-
icardial injury (Wood et al., 2003; Yukumi et al., 2015) or a possible cardiac per-
foration (Turitto et al., 1998; Koller et al., 2004) to be the triggering factors for the 
syndrome. In contrast to the typical onset of PPS, the symptoms generally appeared 
either immediately after the procedure or during the first postoperative day. The 
outstandingly early onset was also presented in a study assessing the incidence of 
PCIS after radiofrequency ablation complicated by cardiac perforation (Liu et al., 
2013), supporting the perforation-based etiology in the aforementioned cases. A 
study containing 303 patients undergoing Nuss procedure, pericarditis occurred in 
7 (2.3%) patients (Croitoru et al., 2002). However, no new PPS cases were de-
tected after the substitution of the introducer into a new model allowing gentle 
dissection of the pericardium away from the underside of the sternum. Overall, 
according to the previous case reports concerning PPS-like states after different 
procedures, penetrating pericardial incision or injury does not seem to be necessary 
for the development of PPS. Instead, PPS appears to require pericardial haemor-
rhage and/or intensive pericardial manipulation as a minimum trigger.  
Besides the younger age, operation type, and summer months, a large prospective 
epidemiological study performed in adult population by Miller and colleagues also 
identified the following as independent risk factors for PPS: lower preoperative 
platelet count, history of prednisone treatment (past or present), history of pericar-
ditis, lower weight, and halothane anesthesia (Miller et al., 1988). Preoperative 
prednisone was given to patients for variety of reasons, but in general the drug was 
used to suppress an inflammatory response, suggesting that these patients may be 
more immunoreactive compared to patients not developing PPS. The fact that PPS 
patients more often had a history of pericarditis suggests that trauma to the peri-
cardium might trigger a recurrence or that these patients are prone to pericarditis. 
Also, despite the number of subjects in this group was low, blood type B– repre-
sented notably higher PPS occurrence. The authors suggested that even though 
PPS was represented in patients with all blood types, certain blood types may pre-
dispose to developing PPS. 
A more recent retrospective study by van Osch and colleagues including 822 pa-
tients undergoing valve surgery found higher BMI to be an independent protective 
factor for PPS (OR per point increase 0.94, 95% CI 0.89–0.99, p=0.028) (van Osch 
et al., 2017a). Treatment for pulmonary disease without corticosteroids was asso-
ciated with a higher risk of PPS (OR 2.55, 95% CI 1.25–5.20, p=0.010). In addi-
tion, contrary to the results of Miller and colleagues (Miller et al., 1988), the uni-
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variable model identified mitral valve surgery as a predisposing factor and pre-
operative corticosteroid use as a protective factor for PPS, in addition to prior 
stroke. The authors suggested that the protective effect of higher weight, also iden-
tified by Miller et al. (Miller et al., 1988), could be related to the immunomodula-
tory effects of obesity, referring to the higher levels of anti-inflammatory ILs (IL-
4 and IL-13) (Zampieri et al., 2015). The higher incidence of PPS in patients with 
pulmonary disease without corticosteroid treatment was presumed to be related to 
the vulnerability of these patients to develop systemic and pericardial inflamma-
tion. 
In a substudy of the COPPS trial assessing the risk factors for PPS, besides female 
sex, pleural incision also was found to be an independent predisposing factor for 
the syndrome (Imazio et al., 2011b). In cardiac surgery, pleural incision may be 
either part of the surgical plan or accidental. If the pleural cavity is entered, it is 
advised to insert a chest tube accordingly (Sellke et al., 2010) which causes pleural 
irritation. The intended or unintended opening of the pleura may also lead to the 
drainage of pericardial fluid through pleural drains via pleural cavity possibly trig-
gering pleuritis and/or PPS which might offer an additional explanation for the 
finding. 
A systematic review published by van Osch and colleagues investigated the risk 
factors for PPS (van Osch et al., 2017b). The review included all major studies 
concerning the risk factors and representing adequate quality. A total of 7 studies 
met the quality requirements. The discrepancy of identified risk factors between 
different studies was striking. Authors presumed this to be due to different defini-
tions of PPS as well as the evolution of surgical techniques during the past 50–60 
years which make it rather impossible to compare the findings of all the studies 
available. Overall, the authors concluded that both the inflammatory response and 
perioperative bleeding and coagulation may play a role in the development of PPS, 
suggesting a multifactorial etiology of the syndrome. The variability in the ob-
served risk factors led to the same conclusions also decades earlier, as Kirsh et al. 
suggested that the syndrome may be a symptom-complex with multiple etiological 
factors (Kirsh et al., 1970). 
2.3.5 Peri- and postoperative characteristics 
Besides the operation type discussed above, many other factors related to the peri- 
and postoperative period have been associated with PPS. As mentioned above, 
halothane anesthesia has been associated with a twofold increase in the incidence 
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of PPS (Miller et al., 1988). The authors presumed this to be mediated by lympho-
cyte stimulation which has been described before in patients with hepatitis 
(Paronetto et al., 1970). 
Only two previous studies have reported the amount of blood transfusions given 
perioperatively in patients with and without PPS (Maisch et al., 1979; van Osch et 
al., 2017a). In the study by Maisch et al. containing overall 65 subjects, patients 
developing definite PPS received 6.3±2.3 units of transfused blood compared to 
5.2±2.4 units given to patients with incomplete PPS and 4.2±2.1 units to patients 
without PPS. In the study by van Osch et al. patients developing PPS also seemed 
to receive more units of packed red cells although it did not reach statistical sig-
nificance (transfusion of ≥2 units packed red cells 23.1% vs. 17.0%, p=0.164). It 
is possible that either the greater amount of perioperative bleeding or the immuno-
logical aspects related to blood transfusions affect the development of PPS, but 
this finding needs to be confirmed before further speculations.  
No laboratory test has been proven to reliably predict the onset of PPS during the 
perioperative period. However, some associations between the laboratory tests and 
PPS have been detected. Miller et al. found that PPS patients had significantly 
lower mean platelet count preoperatively compared to patients not developing PPS 
(Miller et al., 1988). Also, higher mean % lymphocyte cell count was associated 
with PPS after adjustment for age and sex although it did not reach statistical sig-
nificance in the overall multivariable model. A retrospective study by Sevuk et al. 
investigated pre- and postoperative laboratory data in 72 patients with PPS and 
100 control patients who had underwent isolated CABG (Sevuk et al., 2016c). 
There were no differences in the preoperative WBC, neutrophil count, lymphocyte 
count, or neutrophil-to-lymphocyte ratio (NLR). In the postoperative values meas-
ured in the first postoperative day, patients with PPS had significantly higher WBC 
(14.1 vs. 12.0, p<0.001) as well as neutrophil count (11.0 vs. 9.6, p<0.001) with 
no changes in the lymphocyte count (1.2 vs. 1.2, p=0.7) leading to higher NLR 
(8.7 vs. 7.6, p=0.01). The results were also significant in the multivariable model 
(WBC: OR 1.6, 95% CI 1.36–2.03, p<0.001; NLR: OR 3.3, 95% CI 1.56–7.01, 
p=0.002; neutrophil and lymphocyte counts not tested separately). The authors 
suggested the higher postoperative neutrophil count to be a consequence of the IL-
8-mediated chemotaxis which has been associated with PPS (Snefjellå et al., 2012; 
Jaworska-Wilczyńska et al., 2014). The ROC analysis observed a sensitivity of 
60% and specificity of 59% for NLR when using a cut-off value of 8.34. Therefore, 
postoperative NLR or neutrophil count could be useful in the prediction of the 
syndrome, although further studies are needed to confirm these results. The studies 
investigating more specific immunological markers of PPS are detailed below. 
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Heching and colleagues investigated the incidence and risk factors of PPS in pedi-
atric patients following surgical closure of secundum ASD (Heching et al., 2015). 
27 (27.8%) of the included 97 patients developed PPS. A small pericardial effusion 
during the time of discharge was identified in 17 (63.0%) PPS patients, whereas 
only 19 (27.1%) of patients in the non-PPS group presented the effusions 
(p=0.001). The median length of hospital stay was 4 days. Therefore, although 
some of the patients could have developed an active PPS before the discharge, it 
seems that echocardiogram at the time of discharge could have predictive value 
for the syndrome. 
2.3.6 Pathophysiology of PPS 
Soon after the exclusion of the rheumatic etiology, the hypothesis of blood-induced 
delayed hypersensitivity phenomenon, the one also currently believed, was intro-
duced (Engle et al., 1961). It was hypothesized that the syndrome represents a de-
layed hypersensitivity reaction to the presence of damaged tissue in the pericardial 
cavity, whether this was blood, traumatized pericardium, or necrotic muscle (Kirsh 
et al., 1970). Consequently, this material becomes “foreign” protein and thus in-
duces the production of auto-antibody for which the myocardium, red blood cells, 
or the myocardial or pericardial tissues are “target” organs. The immunological 
characteristics were first studied in 1963 (Robinson et al., 1963). Preoperative and 
postoperative hemagglutination tests were performed in 36 patients undergoing 
mitral valvotomy in comparison with 12 patients undergoing non-cardiac thora-
cotomy, 6 patients undergoing laparotomy, and 35 healthy controls. PPS devel-
oped in 6 (16.7%) patients entering the mitral procedure, and the postoperative 
hemagglutination test was positive in 5/6 PPS patients, 1/30 non-PPS patients, and 
0/53 of the patients in the control groups. Therefore, a circulating antibody-like 
substance reacting with heart tissue was suggested to be the pathophysiological 
mechanism of PPS. The results strengthened the theory of an autoimmunological 
reaction and underlined the influence of individual susceptibility to developing the 
disease.  
A year later, van der Gled et al. reported the association of anti-heart antibodies 
(AHA) and PPS (van der Geld, 1964). AHA were detected in the sera of thirteen 
out of fifteen patients with PPS and in eight out of fourteen patients with the Dress-
ler’s syndrome. The number of false positives was reported to be minimal. How-
ever, patients undergoing cardiac procedure without developing PPS were not in-
cluded in the analyses. A prospective double-blind analysis a decade later contain-
ing overall 400 patients confirmed these results (McCabe et al., 1973; Engle et al., 
1974, 1975, 1976, 1980). High rise of AHA was found in 95.4% of PPS cases 
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appearing typically 0–3 days after the clinical signs of the syndrome. Again, the 
specificity as well as sensitivity were excellent. No effect of AHA on the viability 
or growth characteristics of the human heart cells could be seen, and therefore, the 
effect seemed to be either indirect (e.g., via phagocytic function or lymphocyte 
activation) or produced in combination with other blood elements, such as a virus. 
Maisch et al. later reported fairly similar results and also evaluated the appearance 
of three different types of striated muscle antibodies: anti-sarcolemmal antibodies 
(ASA), anti-fibrillary antibodies (AFA), and anti-intercalated disc antibodies 
(AIDA) from which myocardial and skeletal ASA predominated in the complete 
PPS group presenting all the included diagnostic criteria (Maisch et al., 1979). The 
difference was equal in ASA antibodies against heart and skeletal muscle, and thus 
no organ-specificity could be detected. In addition, antibodies against the endothe-
lium of small vessels (AEA) were markedly higher in patients with PPS. The au-
toimmune hypothesis was further strengthened by De Scheerder and colleagues, 
after they observed all the patients with complete PPS (all 3 diagnostic criteria met, 
20.9%) having positive AHA postoperatively, while incomplete and no-PPS 
groups together presented 31.4% of positive AHA (De Scheerder et al., 1985b). 
Moreover, the highest intensity titers were only present in patients with complete 
PPS. It was also found that complete PCIS was associated with the higher ratio of 
postoperative titres of anti-actin and anti-myosin antibodies (De Scheerder et al., 
1985b, 1986, 1991). Because of a large number and extent of different circulating 
antibodies, a general polyclonal hyperimmune response was suggested to have a 
major pathogenetic role in the development PPS (De Scheerder et al., 1991). How-
ever, this hypothesis was soon belied, as no generalized autoantibody production 
was detected in PPS patients (Webber et al., 1992).  
2.3.6.1 Immunology and virology 
A more recent study investigating pre- and postoperative inflammatory markers 
found an association between PPS and lower preoperative IL-8 concentrations 
(Jaworska-Wilczyńska et al., 2014), but the incidence of PPS was 49/75 (65.3%) 
reflecting inappropriate diagnosing and/or insufficient differential diagnostics, and 
therefore these results cannot be applied directly to PPS. Nevertheless, a result of 
higher postoperative level of IL-8 has also been published in another small trial 
(Snefjellå et al., 2012). Therefore, IL-8 might play a role in the pathogenesis of 
PPS. However, a wide range of cells secrete and respond to this chemokine (Qazi 
et al., 2011), and therefore, the deduction of a specific pathogenetic pathways via 
this finding is complicated. The authors suggested that the lower IL-8 concentra-
tion could be related to younger age, as elderly patients may be adapted to an in-
creased level of the cytokines and thus develop less PPS as a consequence to the 
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proinflammatory IL-8 rise resulting from the surgical injury (Jaworska-
Wilczyńska et al., 2014). It is possible that the IL-8 rise results in a chemotactic 
response of neutrophils, as patients with PPS also appear to represent higher neu-
trophil counts in the first postoperative day compared to patients without PPS 
(Sevuk et al., 2016c). This collaboration could possibly be the main pathway the 
prophylactic effect of colchicine is based on, as colchicine, among its numerous 
other functions, inhibits the neutrophil chemotactic response to and production of 
IL-8 (Leung et al., 2015). Also prednisolone seems to have a reducing effect on 
the IL-8 immediately after the operation, although the effect is less substantial than 
the effect on IL-6 and IL-10 (Amanullah et al., 2016). This could explain the 
prophylactic effect of prednisolone detected in some studies (Dresdale et al., 1956; 
Sevuk et al., 2016b). Further studies are needed to confirm the involvement and 
mechanism of IL-8 in the pathogenesis of PPS. 
Driven by the detected annual changes in PPS occurrence (McGuinness et al., 
1962; Drusin et al., 1965), interest in the participation of viruses in the pathogen-
esis of PPS arose. In the study mentioned above by Engle and colleagues, viral 
titers of adenovirus, coxsackie B1–6, and cytomegalovirus were also tested in 280 
patients. Titers for one or more of the viruses were positive in 69.9% of PPS pa-
tients with positive AHA, whereas in patients with negative AHA and no PPS only 
7.8% of patients represented positive results (Engle et al., 1980). Coxsackie B4 
was the most prevalent virus but all viruses tested were presented and the authors 
also observed remarkable annual changes in the viral titers. More than a half of the 
patients with PPS and positive AHA had no detectable viral titers preoperatively 
and then had a rise. Consequently, the hypothesis by Engle and colleagues for the 
pathophysiology was as follows: PPS is the result of an immune response to trau-
matized myocardium with the “neighbourhood” involvement of the pleura. Heart-
reactive antibody (AHA) appears in high titer in the individuals who, because of 
their age and previous immunologic experience, react to the epicardial and myo-
cardial injury incurred at pericardiotomy. The reaction may also be triggered by a 
latent or recent viral illness, or the viral illness may be acquired in connection with 
the operation, perhaps in the operating room while the pericardium is open. Virus 
invasion of the myocardial cells transforms self into non-self, and the AHA is pro-
duced against the neoantigen (Engle et al., 1976, 1980). It has been also suggested 
that immune complexes are formed between the foreign material and the antibody 
engenders. This, in turn, may trigger the complement cascade resulting in the re-
lease of inflammatory agents causing the clinical signs and symptoms (Lessof, 
1976). This hypothesis was strengthened by the study of De Scheerder and col-
leagues, who observed higher rate of positive circulating immune complexes (CIC) 
in patients with PPS (De Scheerder et al., 1984) and by Meri and colleagues, who 
found higher levels of C3 breakdown products during the syndrome (Meri et al., 
1985). As discussed before, it is however possible that the elevation of AHA as 
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well as antiviral antibodies are related to the greater amount of myocardial injury 
presented in more extensive procedures which are also followed by the higher in-
cidence of PPS (Engle et al., 1980). Then again, the higher degree of myocardial 
injury provides higher number of binding sites for antigen-antibody reactions as 
well as higher amount of traumatized tissue for viral invasion. Nevertheless, it has 
to be kept in mind that also conflicting results of the correlation of viral titers 
(Maisch et al., 1979; De Scheerder et al., 1984) as well as AHA (Bufalino et al., 
1983; Baker et al., 1986; Akl et al., 1992; Bartels et al., 1994) and PPS have been 
published, although in markedly smaller settings and often representing differ-
ences in assay techniques and questionable incidences of PPS. In a small prospec-
tive study including only 3 PPS patients, AHA was negative at the time of PPS 
onset but was detected 14 days after the appearance of the symptoms (Hoffman et 
al., 2002). Therefore, AHA appeared to be an epiphenomenon rather than a cause. 
In a prospective study containing 149 children, no correlation was found between 
PPS and the detection of enteroviral genome (Webber et al., 2001). The authors 
discussed that the use of IgG serology for the diagnosing of acute viral infections 
is problematic and can be influenced by many factors, including perioperative 
blood transfusions performed to all patients in majority of the previous studies. 
Therefore, the isolation of the virus itself is necessary, with which no correlation 
was detected in the aforementioned study. Nevertheless, even with the most mod-
ern techniques, the detection of the underlying viruses can be problematic (Maisch, 
2005). 
The participation of B-cell mediated humoral immune system in the pathophysiol-
ogy of PPS is challenged by the fact that the syndrome has been observed also in 
patients receiving immunosuppressants (Cabalka et al., 1995). Most of the children 
received triple-drug immunotherapy with cyclosporin A, azathioprine, and corti-
costeroids after cardiac transplantation. Regardless of this, 7 out of 15 patients de-
veloped PPS appearing 9 to 26 days after the operation. PPS was associated with 
significantly higher proportion of activated helper T cells (CD4+/25+) during the 
2nd month after transplantation when compared to patients without PPS in addition 
to a rise in the activated cytotoxic T cells (Leu-7+/CD8+). The results suggested a 
role for T-cell-mediated immunity in the development of PPS. It was hypothesized 
that initial T-cell activation results in the release of cytokines, which promote in-
flammatory mediator production by local effector cells, such as monocytes and 
macrophages. This secondary release of inflammatory mediators could then lead 
to the clinical manifestations of PPS. 
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2.3.6.2 Other investigations and theories 
The first study assessing the effects of genetics in the development of PPS was 
published in 2017 (Dechtman et al., 2017). The study included overall 45 patients 
with PPS and 41 patients who did not develop the syndrome for 3 months follow-
ing the surgery. The authors determined the three most common MEFV (Mediter-
ranean fever) gene mutations (M694V, V726A, and E148Q) and found no signifi-
cant differences between patients with and without PPS. However, when compar-
ing mild to moderate (n=24) and severe PPS (n=21), the patients with severe PPS 
had significantly less carriage of MEFV mutation (4.8% vs. 25%, p<0.05). The 
authors suggested that this could be mediated by the elevation of the inflammatory 
markers in patients carrying MEFV mutations leading to protective role against 
PPS. Another offered hypothesis was the diversion of balance between inflamma-
tion and apoptosis towards the latter eventually leading to T cell-mediated changes 
in inflammatory reaction. However, the study did not report either the diagnostic 
criteria, the incidence of PPS, or the baseline data in mild-moderate PPS and severe 
PPS separately, and patients with PPS were outstandingly more often female 
(82.3% vs. 42.0%, p=0.0001). Therefore, these results need to be confirmed before 
further speculation. 
Only a few case reports of patients undergoing pericardiectomy due to PPS or the 
autopsy findings of the pericardial space during active recurrent PPS have been 
published (Goodkind et al., 1960; Engle et al., 1961). In these severe cases of PPS, 
an intense pericardial reaction on the epicardium and pericardium was observed, 
in addition to pericardial thickening, loculated blebs of serous pericardial fluid, 
and fibrinous adhesions between the pericardium and epicardium. Previous reports 
of pericardial biopsy in PPS patients are mainly from patients who have undergone 
non-surgical procedures of the heart or non-cardiac procedures. In these cases, the 
histology of the pericardium has been non-specific inflammatory changes by rule, 
featured by fibrous hyperplasia and inflammatory cell invasions (Cevik et al., 
2009; Li et al., 2011; Bialy et al., 2017; Nishimura et al., 2019). Similar changes 
have been detected in the biopsy specimen of pleura (Yukumi et al., 2015; Bujarski 
et al., 2016; Sinha et al., 2016; Nishimura et al., 2019). When specified, the in-
flammatory cells have presented macrophage and lymphocyte predominance 
(Cevik et al., 2009; Yukumi et al., 2015). In a one case report of PPS following 
transdiaphragmatic pericardial window, the pericardium was thickened, contained 
fibrinous lesions, and the histology revealed abundant lymphoid infiltrations stain-
ing heavily for CD138, with rare IgG4 patterns (King et al., 2009). CD138 refers 
to plasma cell infiltrations (Calame, 2001), and IgG4 is usually produced as a re-
sponse to chronic exposure to antigens “blocking” the pathogenic effector mecha-
nisms of other antibody species (Koneczny, 2018). These findings support strongly 
the hypothesis of antigen revelation as the triggering factor for PPS. 
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Bufalino and colleagues studied the use of gallium-67 scan in the diagnosing of 
PPS (Bufalino et al., 1983). They found that patients developing PPS during the 
early postoperative period presented negative scanning, whereas patients develop-
ing PPS after 2 weeks presented positive scanning. This led the authors to the con-
clusion that latent PPS might represent the “classic” immune-mediated syndrome, 
whereas the patients with early PPS appearing within 8 days postoperatively may 
have traumatic pericarditis, or less dense inflammatory response and thus a nega-
tive gallium-67 uptake. Later, the scan was found to be negative in patients with 
Dressler’s syndrome, suggesting separate etiologies also for the two diseases 
(Hutchison et al., 1987). 
Besides the prevailing view of the pathophysiological mechanism of PPS, other 
less-investigated hypotheses have been suggested. One of the theories was pro-
posed by Osborne et al., who suggested that starch pericarditis, induced by the 
starch powder used in the surgical gloves, could be one of the several mechanisms 
of PPS (Osborne et al., 1974). Although the starch could, theoretically, be one of 
the etiological agents, this mechanism would not quite explain the cases following 
intravenous pacemaker implantations and other non-surgical procedures. CPB has 
been also discussed to be a contributory factor in the pathogenesis of PPS (Tárnok 
et al., 2001). A major involvement of CPB as well as the factors related to it is 
unlikely, as during the first descriptions of the disease, CPB was an unestablished 
part of cardiac procedures and not a part of common practice (Sellke et al., 2010). 
Moreover, in the patients undergoing cardiac surgery involving the heart-lung ma-
chine, PPS develops just as in the patients without (Engle et al., 1978; Kaminsky 
et al., 1982; Jaworska-Wilczyńska et al., 2014). 
2.3.6.3 Retained blood theory 
The concept of retained blood syndrome (RBS) was first established in the year 
2015 (Boyle et al., 2015). RBS covers a spectrum of mechanical and inflammatory 
complications related to drainage system failure to adequately evacuate blood after 
cardiac surgery. According to the aforementioned article, the diagnostic criteria for 
the syndrome are specified as at least one of the following: 1) pleural effu-
sion/hemothorax requiring drainage, 2) pericardial effusion requiring drainage, 3) 
re-exploration for washout of blood, 4) interventions for postoperative pericardial 
constriction, and 5) interventions for postoperative fibrothorax. Therefore, there is 
an obvious overlap within the entities of PPS and RBS. The authors went on to 
state that RBS is the root cause of PPS via the acute, subacute, and chronic inflam-
matory response the retained blood triggers. It was suggested that once the retained 
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blood clots within the pericardium or pleural space, thrombin and fibrin are gener-
ated. These products are powerful chemoattractants of inflammatory cells that can 
stimulate the mesothelial cells of the pericardium and pleura to release inflamma-
tory cytokines. As stated above, it seems that PPS requires pericardial haemor-
rhage and/or intensive pericardial manipulation as a minimum trigger. Therefore, 
the hypothesis of Boyle and colleagues seems logical, although the inadequate 
blood evacuation does not seem necessary for the onset of PPS, as no previous 
studies have reported excessive pericardial blood collections to be in association 
with PPS. It needs to be taken into consideration, however, that the accuracy of 
transthoracic echocardiography, the examination typically included in the diagnos-
tic evaluation of PPS, in detecting pericardial effusion/hematoma is limited 
(Floerchinger et al., 2013). Nevertheless, it seems likely, that even minimal 
amount of pericardial blood can serve as a trigger for the syndrome, and even 
though the active techniques to enhance the surgical drainage appear to reduce the 
development of postoperative new-onset AF (Sirch et al., 2016), it is unlikely that 
they would eliminate the entity of PPS. Still, the pathophysiological mechanism 
suggested by the authors seems conceivable. Also, according to previous studies, 
it seems plausible that the extended chest tube drainage as well as posterior peri-
cardiotomy could reduce late tamponade related to PPS (Gozdek et al., 2017; Khan 
et al., 2019). 
2.4 Management of PPS 
2.4.1 Medical treatment 
The investigations concerning possible methods for the treatment and prevention 
of PPS started rapidly after the first description of the syndrome. The value of 
corticosteroids in the treatment of PPS was shortly observed (Soloff et al., 1953; 
Dresdale et al., 1956). Also NSAIDs were found to be efficacious (Elster et al., 
1954), and later they were recommended as the first-line treatment for the milder 
presentations of PPS (Uricchio, 1963; Engle, 1983; Nishimura et al., 1983; 
McClendon et al., 1986; Engle et al., 1987), whereas corticosteroids were recom-
mended for the most severe clinical presentations (McClendon et al., 1986; Engle 
et al., 1987).  
Later, both NSAIDs and corticosteroids, in addition to colchicine, have been in-
vestigated in double-blind, placebo-controlled settings. In a trial including overall 
149 PPS patients, both ibuprofen and indomethacin administered for 10 days re-
lieved symptoms and shortened the duration of the illness without considerable 
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side effects (Horneffer et al., 1990). Another trial including 21 patients with PPS 
found that a two-week corticosteroid treatment increased the one-week remission 
rates and fastened the time to symptom relief (Wilson et al., 1994). However, the 
use of corticosteroids in the treatment of pericarditis is no longer recommended as 
it has been associated with higher recurrence rate (Artom et al., 2005; Imazio et 
al., 2005a, 2005b, 2005c, 2013b; Adler et al., 2015). As stated before, however, 
evidence against their use in postsurgical pericardial syndromes are scarce 
(Cantinotti et al., 2014). In most of the aforementioned studies, the number of pa-
tients using corticosteroids were small, the drug was only administered in case of 
aspirin contraindications or failure, and the durations of the treatments were rela-
tively short. Moreover, the notably effective response during the treatment leading 
to too rapid tapering is a typical pitfall of corticosteroid use, and rather than aban-
doning the drug it should be used with awareness and slow tapering, and routine 
administration during the first episode should be avoided (Adler et al., 2015; 
Imazio et al., 2019). Colchicine has been found to be effective in the most persis-
tent cases of PPS (Tenenbaum et al., 2004), and it has been also associated with a 
decreased need for invasive interventions (Alraies et al., 2014). The ICAP trial 
focused on the benefits of first-line use of colchicine in the treatment of acute per-
icarditis including overall 48 (20.0%) PCIS patients found a significant reduction 
in the rate of symptom persistence at 72 hours (19.2% vs. 40.0%, p=0.001), the 
number of recurrences (16.7% vs. 37.5%, p<0.001), and the hospitalization rate 
(5.0% vs. 58.3%, p<0.001) and increased remission rate at one week (85.0% vs. 
58.3%, p<0.001) (Imazio et al., 2013b). Multiple meta-analyses have confirmed 
the efficacy of colchicine both in the first-line treatment of pericarditis as well as 
in the secondary prevention of recurrent episodes (Alam et al., 2012; Imazio et al., 
2012, 2014b; Agarwal et al., 2015; Li et al., 2016; Wang et al., 2016; Papageorgiou 
et al., 2017). 
According to the current guidelines, the treatment of PPS is based on the use of 
NSAIDs and colchicine, with the occasional addition of corticosteroids. Although 
symptomatic effusions require medical treatment, the management of asympto-
matic effusions is controversial. Recommended doses for uncomplicated cases in-
clude aspirin 750–1000 mg or ibuprofen 600 mg every 8 hours with a duration of 
1–2 weeks followed by tapering. Colchicine should only be used in the presence 
of systemic inflammation, and the recommended dose is 0.5 mg once (<70 kg) or 
twice (≥70 kg) daily for 3 months with an optional halving of the dose in the last 
weeks of the treatment. Corticosteroids should be considered as a second option in 
patients with contraindications and the failure of NSAIDs with low to moderate 
doses (i.e., prednisone 0.2–0.5 mg/kg/day or equivalent) (Adler et al., 2015). 
According to few case reports, methotrexate (Zucker et al., 2003), azathioprine 
(Marcolongo et al., 1995; Vianello et al., 2011), as well as high-dose intravenous 
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immunoglobulin (Wendelin et al., 2008; Moretti et al., 2013; del Fresno et al., 
2014; Imazio et al., 2016), may be effective if a patient with PPS develops depend-
ency on steroids. In chronic recurrent pericarditis, also anakinra, a recombinant IL-
1β receptor antagonist (Lazaros et al., 2014, 2016) as well as cyclophosphamide 
(Marcolongo et al., 1995) have been successfully used. Moreover, intrapericardial 
triamcinolone has been used in the treatment of chronic autoreactive pericardial 
effusion (Maisch et al., 2002), and it is also mentioned in the ESC guideline as 
well as azathioprine, intra-venous immunoglobulin, and anakinra (Adler et al., 
2015). 
2.4.2 Interventional treatment 
If the patient has evidence of clinical tamponade or if the symptoms persist regard-
less of the medical treatment and an alternative diagnosis is suspected, the evacu-
ation of pericardial effusion is required (Engle et al., 1978; Adler et al., 2015). In 
the presence of tamponade, the needle pericardiocentesis is preferred, whereas sur-
gical approach might be safer when the pericardial fluid is not free, it is located in 
a lateral or posterior position, or the effusion is mild (<10 mm). The pericardio-
centesis should be performed under guidance either by fluoroscopy or echocardi-
ography and under local anesthesia. The ideal entry site in the echocardiography-
guided procedure is the point where the effusion is closest to the transducer and 
the fluid collection is maximal and the liver or pleura are not on the way, whereas 
in the fluoroscopy-guided procedure the subxiphoid route is more common. If 
there is a need for pericardial biopsy for the differential diagnostics, the surgical 
approach is the gold standard, classically through a subxiphoid incision. In this 
procedure, a small drain is left in place to evacuate any remaining effusion (Adler 
et al., 2015). In the presence of extensive pleural effusions, a pleural drainage or 
thoracocentesis may be required, and they should be preferably performed on ul-
trasound-guidance. The drain should be inserted in the “triangle of safety”, refer-
ring to the area bordered by the lateral edge of the latissimus dorsi, the lateral bor-
der of the pectoralis major muscle and superior to the horizontal level of the fifth 
intercostal space (Havelock et al., 2010). 
In the most persistent cases of pericardial effusion, pericardiectomy may be con-
sidered (Adler et al., 2015). Fortunately, this is needed only in extremely rare cases 
(Engle et al., 1978). Other possible interventional treatments include prolonged 
pericardial drainage, the aforementioned intrapericardial triamcinolone treatment, 
and pericardial window (Adler et al., 2015). The pericardial window can be per-
formed either by conventional heart surgery, by thoracoscopy, or by balloon peri-
cardiotomy by inserting a deflated single catheter or double balloon catheters into 
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the pericardial space (Imazio et al., 2017). If the surgery is performed, pericardi-
ectomy is the procedure of choice, because pericardial window may not relieve 
loculated pericardial fluid or may close soon after being performed (Ofori-Krakye 
et al., 1981; Adler et al., 2015). If the persistent PPS manifests as large, sympto-
matic pleural effusions continuing despite several thoracocenteses, thoracoscopy 
should be considered. At thoracoscopy, any fibrous tissue coating the visceral 
pleura should be removed and either the parietal pleura should be abraded or talc 
should be used to create a pleurodesis (Light, 2002; Paull et al., 2003). In addition, 
a single case report has been published of the use of indwelling pleural catheter for 
the recurrent pleural effusions secondary to PPS (Bujarski et al., 2016). 
2.4.3 Prevention 
The first study concerning PPS prophylaxis was published in 1956 (Dresdale et 
al., 1956). A prophylactic 3–8 weeks cortisone treatment postponed the develop-
ment of PPS and resulted in a less stormy immediate postoperative course, alt-
hough the incidence of PPS was similar after drug withdrawal (29 vs. 31%). Later, 
a double-blind placebo-controlled study including 246 children found no effect of 
short-term prophylactic intravenous methylprednisolone (1 mg/kg before CPB 
plus four additional doses within 24 hours) on the incidence of PPS (Mott et al., 
2001). Instead, a greater proportion of the treatment group developed PPS leading 
to hospital admission (6.3% vs. 0.8%). A substudy of the DECS trial investigated 
the effect of intraoperative dose of 1 mg/kg dexamethasone in 822 adults and found 
no benefits in either the occurrence of PPS or complicated PPS (Bunge et al., 
2014). On the other hand, a retrospective study including overall 200 adult patients 
reported significant PPS reduction in patients receiving a single intraoperative dose 
of 1 mg/kg methylprednisolone (22.0% vs. 37.0%, p<0.026) (Sevuk et al., 2016b). 
It has been suggested that the positive result conflicting with previous studies could 
be due to the strict exclusion criteria used (Wamboldt et al., 2018). Further large-
scale studies are needed to assess the possible value of corticosteroids in the pre-
vention of PPS maintaining special focus on the exact timing and route of the drug 
administration (Wamboldt et al., 2018). 
A prospective study evaluating the effect of one week aspirin prophylaxis (60 
mg/kg/day) in children found no significant reduction in the size of postoperative 
pericardial effusions (Béland et al., 1990). This finding has been supported by later 
studies in children and young adults (Gill et al., 2009; Rabinowitz et al., 2018). By 
contrast, a retrospective study evaluating the effect of diclofenac treatment for 
postoperative analgesia during the hospital admission  in 100 adult patients found 
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a significant reduction in PPS occurrence when compared to patients not adminis-
tered to NSAIDs (20.0% vs. 43.0%, p=0.001) (Sevuk et al., 2015). However, no 
prospective trials have yet confirmed this finding. 
The first trial reporting the possible value of colchicine for the prevention of PPS 
was published in 2002 (Finkelstein et al., 2002). After that, two randomized, pla-
cebo-controlled trials have been published accordingly. The COPPS trial included 
overall 360 adult cardiac surgery patients, from which 180 received placebo and 
180 received colchicine for a month postoperatively. Colchicine significantly re-
duced the incidence of PPS (8.9% vs. 21.1%, p=0.002, NNT=8) and PPS-related 
hospitalization, cardiac tamponade, constrictive pericarditis, and relapses (0.6% 
vs. 5.0%, p=0.024). A few years later the COPPS-2 trial included another 360 adult 
cardiac surgery patients, from which 180 received colchicine starting two to three 
days preoperatively and continuing until 1 month after the surgery. Again, the ad-
ministration of colchicine resulted in a significant reduction of PPS (19.4% vs. 
29.4%, NNT=10). The effect was significantly higher in patients with systemic 
inflammation, specified as an elevation of C-reactive protein (CRP) during the 
hospital admission. This time, no significant reduction in the PPS-related second-
ary end points was detected. The three aforementioned studies have been also an-
alysed using meta-analytic pooling that has shown a relative risk reduction of 44–
52% in PPS incidence (Agarwal et al., 2015; Briasoulis et al., 2015; Wang et al., 
2016; Papageorgiou et al., 2017). Therefore, colchicine seems effective in the pre-
vention of PPS, although its use is limited by the gastrointestinal side effects. Ac-
cording to previous studies, colchicine causes an increment of 8–10 percentage 
points in gastrointestinal side effects compared to placebo but serious side effects 
have not been observed (Finkelstein et al., 2002; Imazio et al., 2005a, 2010, 2012, 
2013b, 2014b; Alam et al., 2012; Agarwal et al., 2015; Wang et al., 2016; Li et 
al., 2016; Papageorgiou et al., 2017). The effect is worsened if the drug is started 
preoperatively (Imazio et al., 2014c). 
Currently, because of the relatively good outcome of PPS patients and the adverse 
effects of colchicine, instead of the primary prevention, clinicians are advised to 
consider early recognition and treatment of the syndrome (Adler et al., 2015; 
Imazio, 2015). However, according to the ESC Guideline, a one-month colchicine 
prophylaxis should be considered after cardiac surgery for the prevention of PPS 
if there is evidence of systemic inflammation, there are no contraindications, and 
the drug is tolerated (class IIaA recommendation).  
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2.5 Prognosis after PPS 
According to previous studies, PPS is associated with a prolonged hospital stay 
(Engle et al., 1975; Maisch et al., 1979; Imazio et al., 2011b; van Osch et al., 
2017a) and readmissions (Mott et al., 2001; Imazio et al., 2011b; Bunge et al., 
2014). The reported recurrence rates have varied between 4% and 21% and typical 
timing of the repeating episodes is from 1 to 3 months after the first episode 
(Drusin et al., 1965; Nishimura et al., 1983; Imazio et al., 2011b). The incidence 
of PPS-related cardiac tamponade is 0.8–1.3% after the first week after cardiac 
surgery, making PPS the most common etiology of delayed cardiac tamponade 
(Bortolotti et al., 1981; Ofori-Krakye et al., 1981). The tamponade can occur any-
where between 7 and 180 days after the operation. In a recent study, PPS was as-
sociated to an over 15-fold risk of reoperation for tamponade (van Osch et al., 
2017a). 
Apart from the aforementioned complications, the previous knowledge of PPS-
related adverse events is limited. A study including 100 patients undergoing mitral 
valvotomy found no association between PPS and new-onset AF (Papp et al., 
1956). Another retrospective study including 60 patients developing postoperative 
atrial fibrillation (POAF) and 142 patients without POAF after CABG found a 
significant association between POAF and PPS (incidence of PPS after POAF 
(61.7%) vs. no-POAF (45.8%), OR 1.9, 95% CI 1.03–3.5, p=0.04) (Sevuk et al., 
2016a). However, there were multiple baseline differences between the study 
groups, and the incidence of PPS was strikingly high (overall incidence 51%) re-
flecting either selection bias or problems with the differential diagnostics of PPS 
and also questioning the main results.  
Constrictive pericarditis has been suggested to be a complication of PPS appearing 
during long-term follow-up (Imazio, 2012). An analysis including 37 constrictive 
pericarditis patients with adequate clinical information, PPS was observed in 23 
(62.2%) patients (Killian et al., 1989). Similar results have been reported in several 
studies (Rice et al., 1981; Miller et al., 1982). However, another analysis including 
5207 cardiac surgery patients, 11 cases of constrictive pericarditis were observed, 
but only one presented acute pericarditis during the postoperative period (Kutcher 
et al., 1982). According to the aforementioned studies, constrictive pericarditis oc-
curs in a broad time frame of 1 month to 17 years postoperatively, typically within 
24 months, with an overall incidence of 0.2–0.3%. Assuming 60% of constrictive 
pericarditis would be of PPS-related etiology, approximately 0.5% of the patients 
with PPS would develop constrictive pericarditis during long-term follow-up. This 
incidence is similar to idiopathic/viral pericarditis (Imazio et al., 2011a). However, 
markedly higher incidences of constrictive pericarditis have also been reported 
(Alraies et al., 2014), although possibly reflecting the selection bias of the original 
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patient selection as stated also by the authors themselves. Only one prospective 
study has evaluated the rate of constrictive pericarditis after PCIS (Imazio et al., 
2011a). However, even though PCIS was combined with connective tissue dis-
eases, the number of patients was insufficient (n=36) to draw any conclusions. 
Another study including 119 PPS patients with a follow-up of one year found no 
constrictive pericarditis cases (van Osch et al., 2017a). Therefore, the question of 
whether constrictive pericarditis is associated to the development of PPS or to a 
common pathophysiological trigger, e.g., surgery related hemopericardium, is con-
troversial. Either way, the presence of PPS should serve as a warning signal to 
clinicians, as a theoretical risk of constriction exists (Adler et al., 2015). 
Symptomatic treatment of PPS has been associated with a higher incidence of ve-
nous graft occlusion when compared to patients receiving NSAIDs and predniso-
lone for a time period of 6 weeks (Urschel et al., 1976). The patients were observed 
to have diffuse adhesions between the pericardium and epicardium, often oblite-
rating the pericardial space. The venous grafts had microscopical fibrinoid degen-
eration and infiltration by chronic inflammatory cells suggesting external compres-
sion rather than intimal hyperplasia as the cause of the stenosis or occlusion. How-
ever, similar results have not been reported since apart from a single case report of 
a patient developing rapid coronary artery occlusion after PPS (De Scheerder et 
al., 1985a). Other reported possible complications include the extrusion of the 
pulse generator from the pacemaker pocket (Wang et al., 1983) and the thickening 
and scarring of autogenous pericardial baffle (Luken et al., 1986). 
Van Osch et al. have published the largest study focusing on the prognosis of PPS 
(van Osch et al., 2017a). This retrospective subanalysis of the DECS trial included 
822 patients undergoing valve surgery followed up to a year postoperatively. Over-
all 119 (14%) patients developed PPS. Patients with PPS presented markedly more 
reoperations for tamponade at one year (20.9% vs. 2.5%, OR 15.49, 95% CI 7.14–
33.58, p<0.001) with the difference appearing within two months after the surgery 
in addition to longer hospital stay (13 vs. 11 days, p=0.001). However, the one-
year prognosis was interpreted excellent: 4/119 (4.2%) of PPS patients and 37/703 
(5.5%) of patients without PPS died during the first year after the surgery (OR 
0.63, 95% CI 0.22–1.79, p=0.497). Also, no significant associations were observed 
between PPS and reoperation for surgical bleeding, pleural puncture, postoperative 
AF, stroke, myocardial infarction, or readmissions.  
The aforementioned study is the only study evaluating the effect of PPS on mor-
tality. Therefore, the previous knowledge of the benignity of PPS is somewhat un-
certain. Despite the limited published data, the prognosis of PPS has been consid-
ered to be benign (Bucekova et al., 2012; Imazio et al., 2013d; Adler et al., 2015). 
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3 AIMS OF THE STUDY 
The principal aims of the study were to: 
 
1. Evaluate the incidence and risk factors for PPS requiring medical attention. 
 
2. Investigate the effect of sex, age, and procedure type on the occurrence of 
PPS. 
 
3. Examine the prognosis after PPS. 
 
4. Estimate the role of PPS-related adverse events in the higher mortality after 
PPS. 
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4 MATERIALS AND METHODS 
4.1 Patient populations 
In the study I, the study population included a consecutive series of 699 patients 
who had undergone an isolated CABG between 2008 and 2010. All operations 
were performed in Turku University Hospital, Turku, Finland. The follow-up was 
complete for 688 (98.4%) patients.  
The study II included all patients admitted to a hospital with PPS as a primary 
cause of admission between May 2000 and October 2009 in 29 hospital in Finland 
nationwide. Only patients aged 20–79 years were included resulting in 760 PPS 
patients.  
The population of the study III included overall 28,761 consecutive adult patients 
entering CABG, AVR, MVR, or ascending aortic surgery in Finland between Jan-
uary 2005 and December 2013. The data included cardiovascular admissions from 
131 health care units nationwide. Overall 493 PPS episodes severe enough to re-
quire hospital admission or contributing to death were identified. The study popu-
lation flow chart is presented in Figure 3.  
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Figure 3. Study population flow chart for the study III. Modified from the original publication 
III, Figure 1. AVR: aortic valve replacement; CABG: coronary artery bypass grafting. 
The study IV contained patients from two separate databases. Majority of the pa-
tients (n=622) were from the multicenter (university hospitals of Turku, Oulu, and 
Kuopio), retrospective CAREAVR database and the remaining patients (n=49) 
were from the prospective, single-center (Turku University Hospital) CARE-
BANK database resulting in a combination database of 671 patients. The patients 
underwent an isolated SAVR with a bioprosthesis (n=361) or a mechanical pros-
thesis (n=310) over the period of 2002–2014 (CAREBANK: 2016–2018).  
4.2 Study designs 
The study I was a retrospective cohort study. The data on baseline and periopera-
tive characteristics, discharge medication, and postoperative outcomes were col-
lected from electronic patient records. Follow-up data were retrieved from the 
catchment areas of Turku University Hospital, Turku City Hospital, and Satakunta 
Central Hospital. The median follow-up time was 5.3 years. The causes and timing 
of death were derived from Statistics Finland.  
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The studies II and III were retrospective cohort studies using data collected from 
the nationwide Care Register for Healthcare database, maintained by the Finnish 
National Institute for Health and Welfare. This database contains basic baseline 
data (e.g., age and sex), data on the length of hospital stay, performed procedures, 
and International Classification of Diseases, Tenth Revision (ICD-10) diagnostic 
codes for all hospital admissions in Finland nationwide. In the study II, age- and 
gender-matched population data from Statistics Finland was also used to specify 
the incidence rates in the overall Finnish population. In addition, the numbers of 
cardiac procedures were estimated using the Blood Products in Cardiac Surgery 
(BiCS) database, maintained by Finnish Red Cross Blood Service. In the study III, 
the data on causes and timing of death were derived from Statistics Finland. 
The study IV contains data from two separate databases included in the CAREFIB 
Consortium: CAREAVR (Consortium of Studies in the Field of Atrial Fibrillation, 
Stroke, and Bleeding in Patients Undergoing Aortic Valve Replacement; Clinical-
Trials.gov Identifier: NCT02626871) and the CAREBANK (Cardiovascular Re-
search Consortium - a Prospective Project to Identify Biomarkers of Morbidity and 
Mortality in Cardiovascular Interventional Patients; ClinicalTrials.gov Identifier: 
NCT03444259). The CAREAVR is a Finnish multicenter retrospective study con-
taining patients undergoing isolated SAVR in four Finnish university hospitals 
(Helsinki, Turku, Oulu, and Kuopio). Helsinki was excluded from the study IV 
due to incomplete follow-up data for PPS. The electronic patient records were re-
viewed with a standardized structured data collection protocol for pre- and periop-
erative data, discharge data, and long-term follow-up events, including POAF, 
stroke, transient ischemic attacks (TIA), bleeding events, and mortality. The 
CAREBANK is an ongoing Finnish prospective cohort study assessing the associ-
ations between the features of cardiac tissue samples and clinical phenotypes in 
patients undergoing cardiac procedures in Turku University Hospital. In the study 
IV, only patients undergoing isolated SAVR were included. The data were col-
lected from electronic patients records and by follow-up phone calls at 3, 12, 24, 
and 60 months. A standardized structured data collection protocol similar to the 
CAREAVR study was used allowing the combination of the two databases. The 
data on causes and timing of death were derived from Statistics Finland. In the 
combination database, the median follow-up time was 9.0 years for survival and 
5.1 years for the other adverse events. 
4.3 Outcomes 
Study I  
The primary outcome of the study I was PPS requiring medical attention. PPS was 
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defined by the presence of at least 2 of the following: 1) fever without alternative 
causes, 2) pleuritic chest pain, 3) friction rub, 4) evidence of new or worsening 
pleural effusion, and 5) evidence of new or worsening pericardial effusion, based 
on the previously proposed criteria for scientific purposes (Imazio et al., 2013c). 
Secondary outcomes included PPS relapse defined by the worsening of pericardial 
or pleural effusion while on medication or after the withdrawal of medication, the 
evacuation of pleural or pericardial effusion due to PPS, and all-cause death.  
Study II  
The primary outcome of the study II was PPS leading to hospital admission. Pa-
tients with PPS as the primary cause of admission were identified by ICD-10 code 
I97.0. Readmissions due to PPS were also included. The data of the study I were 
used to evaluate the pre-, peri-, and postoperative factors between patients included 
in the study II and the remaining PPS patients to assess the possible selection bias. 
Validation showed no significant differences between the PPS patients included in 
the study II and the remaining PPS cases.  
Study III  
In the study III, the primary outcome was PPS severe enough to require hospital 
admission or contributing to death. Postoperative admissions with PPS as the pri-
mary, secondary, or tertiary cause of admission, or as any cause of death were 
identified using ICD-10 code I97.0. The secondary outcome was 1-year all-cause 
mortality. 
Study IV  
The primary outcome of the study IV was PPS requiring medical attention defined 
by the presence of at least two of the following criteria: 1) fever without alternative 
causes, 2) pericarditic or pleuritic chest pain, 3) pericardial or pleural rubs, 4) evi-
dence of pericardial effusion, and 5) evidence of pleural effusion with elevated C-
reactive protein (CRP), based on the criteria recommended by the ESC guideline 
(Adler et al., 2015). PPS was categorized into two subgroups according to the se-
verity of the syndrome: moderate PPS which did not require invasive interventions, 
i.e., the evacuation of pleural or pericardial effusion, and severe PPS which re-
quired invasive interventions such as pericardial or pleural drainage. Secondary 
outcomes included new-onset AF, stroke, major stroke, TIA, major bleeding, and 
all-cause death. Stroke was defined as a permanent focal neurological deficit ad-
judicated by a neurologist and confirmed via computed tomography or magnetic 
resonance imaging. Major stroke was defined as a stroke other than lacunar-type 
(< 20 mm in diameter). TIA was defined as a transient (< 24 hours) focal neuro-
logical deficit adjudicated by a neurologist. Major bleed was defined as an overt, 
actionable sign of haemorrhage requiring diagnostic studies, hospitalization, or 
treatment by a health care professional. 
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4.4 Statistical analysis 
The statistical analyses were performed using SPSS software, SAS, and R soft-
ware. In the study I, SPSS statistical software version 22.0 (IBM SPSS Inc, Ar-
monk, NY) was used for all the statistical analyses. The analyses of the studies II 
and III were conducted using SAS system version 9.4 (SAS Institute Inc, Cary, 
NC), in addition to SPSS version 24.0 (IBM SPSS Inc, Chicago, IL) in the study 
III. All the statistical analyses of the study IV were conducted with R software 
version 3.3.3 (https://www.R-project.org/).  
Continuous variables were reported as mean ± standard deviation if normally dis-
tributed and as median (25th – 75th percentiles) if skewed. The data were tested for 
normal distribution using Shapiro-Wilk and Kolmogorov-Smirnov tests. Categor-
ical variables were described as counts and percentages. In all studies, p-values < 
0.05 were considered statistically significant. 
Study I  
Chi-square test, Mann-Whitney test, and Cox regression were used to analyse the 
baseline differences and mortality between patients with and without PPS. The 
multivariable analysis was performed using the Cox regression backward stepwise 
selection procedure. The multivariable model was performed by including varia-
bles of relevance with a p-value < 0.10 in the univariable analyses. Metformin was 
excluded due to its association with diabetes, and abnormal use of red blood cell 
units was excluded due to its association with the use of 1 or more red blood cell 
units. The Kaplan-Meier method was used to present survival curves.  
Study II  
The data of the study II was analysed by using negative binomial regression mod-
els. In the model for incidence rates and in the model for estimating the amount of 
PPS compared to the number of cardiac surgeries, the logarithms of age- and gen-
der-specific population and number of cardiac surgeries were used as offset pa-
rameters. Analyses were adjusted for study year. Total incidence rates were stand-
ardized with the European 2013 standard population by using a direct method. 
Study III  
Cox regression univariable and multivariable models were used for studying the 
hazard of PPS and the association between PPS and mortality. The multivariable 
model was performed by including age, sex, Chalson Comorbidity Index (CCI), 
the urgency of the procedure, procedure type, and resternotomy. The associations 
between concomitant CABG in valve and aortic procedures, the use of LITA in 
CABG, and the use of a mechanical valve in AVR and the occurrence of PPS were 
studies by subgroup analyses.  
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Study IV  
Unpaired t-test, Mann-Whitney test, and Cox regression were used for the univar-
iable analyses of the baseline differences between patients with and without PPS. 
The independency of the predictors of PPS was evaluated using Cox regression 
model with interaction terms. The multivariable Cox regression models of the sec-
ondary outcomes were performed by including variables of relevance with a p-
value < 0.10 in the univariable analyses. Survival analyses were adjusted for Eu-
roSCORE II (European System for Cardiac Operative Risk Evaluation) (Nashef et 
al., 2012). Cause-specific competing risk hazard models accounting for death were 
used for analyses of other outcomes than mortality.  
4.5 Ethics 
Studies I-IV were conducted according to the principles of the Declaration of Hel-
sinki. The study protocols were approved by the local ethics committees and the 
ethics committee of the National Institute for Health and Welfare in Finland. An 
informed consent was obtained from the participants of the CAREBANK study. 
Because of the retrospective, observational nature of the remaining studies, an in-
formed consent was not required. 
 Results 49 
5 RESULTS 
5.1 Risk factors and incidence of PPS requiring medical attention 
(study I) 
In the study I, overall 61 of 688 patients (8.9%) undergoing CABG developed PPS 
leading to delayed hospital discharge, readmission, or medical therapy due to 
symptoms. The median latency between the operation and PPS onset was 21 (11–
52) days. The freedom from PPS after isolated CABG is detailed in Figure 4. 
 
Figure 4. Freedom from PPS in patients undergoing isolated CABG. Reproduced from the orig-
inal publication I, Figure 1. PPS: postpericardiotomy syndrome. 
The symptoms of PPS occurred according to the following: pleuritic chest pain 
20%, dyspnea 44%, and fever 41%. Typical clinical findings included pericardial 
effusion (93%), positive chest x-ray (pleural effusion or cardiac silhouette enlarge-
ment, 93%), abnormal erythrocyte sedimentation rate (90%), abnormal CRP 
(84%), and positive electrocardiogram (widespread ST-segment elevations, 45%). 
Friction rub was detected in only 6.9% of the PPS patients.  
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Baseline characteristics and operative data in patients with and without PPS are 
detailed in Table 2. Patients with PPS had less often diabetes and were less often 
taking metformin treatment. Postoperative characteristics of patients with and 
without PPS are detailed in Table 3. Patients with PPS had more often red blood 
cell units transfused in addition to a nonsignificant trend towards more postopera-
tive bleeding. Although also the abnormal use (1–2 units) of red blood cell units 
was significantly associated with higher PPS occurrence, the use of one or more 
units had a stronger presumption against null hypothesis.  
Table 2. Baseline characteristics and operative data in patients with and without PPS. Modified 
from the original publication I, Table 1.  
 PPS 
N=61 
No-PPS 
N=627 P-value 
Age (years) 67 (59–74) 67 (60–73) 0.95 
Females 13 (21%) 141 (23%) 0.83 
BMI 28 (25–30) 28 (25–31) 0.32 
Diabetes 7 (12%) 190 (31%) 0.002 
Hypertension 58 (95%) 590 (94%) 0.83 
Pulmonary disease 3 (4.9%) 49 (7.8%) 0.41 
Atrial fibrillation 3 (4.9%) 49 (7.8%) 0.41 
Extracardiac arteriopathy 1 (1.6%) 50 (8.0%) 0.071 
Prior stroke or transient ischemic attack  3 (4.9%) 44 (7.0%) 0.54 
Prior percutaneous coronary intervention 10 (16%) 110 (17%) 0.92 
Prior cardiac surgery 0 (0.0%) 14 (2.2%) 0.24 
Recent AMI 14 (23%) 130 (21%) 0.76 
Two or three-vessel disease 57 (93%) 600 (96%) 0.34 
Left main stenosis 32 (53%) 280 (44%) 0.20 
Left ventricular ejection fraction <30% 5 (8.2%) 43 (6.9%) 0.70 
Emergency operation 7 (12%) 94 (15%) 0.46 
Urgent or emergency operation 33 (54%) 320 (51%) 0.65 
Preoperative IABP 2 (3.3%) 5 (0.8%) 0.065 
Off-pump surgery 8 (13%) 71 (11%) 0.68 
At least one mammary artery graft 60 (98%) 600 (95%) 0.28 
Radial artery graft 4 (6.6%) 47 (7.5%) 0.79 
No. of distal anastomoses 3.0 (2.0–3.0) 3.0 (2.0–3.0) 0.84 
Preoperative labs:    
     INR 1.0 (1.0–1.1) 1.1 (1.0–1.1) 0.054 
     Hemoglobin 140 (130–150) 140 (130–150) 0.72 
     EGFR 70 (62–83) 77 (65–90) 0.069 
Preoperative medical treatment:    
     Aspirin 60 (98%) 580 (95%) 0.20 
     Clopidogrel 14 (23%) 100 (17%) 0.22 
     LMWH 13 (21%) 160 (27%) 0.34 
     Warfarin 5 (8.2%) 52 (8.5%) 0.93 
     Statin 61 (100%) 590 (95%) 0.074 
     GP IIa/IIIb –inhibitors 2 (3.3%) 24 (3.8%) 0.83 
     Thrombolysis 0 (0.0%) 17 (2.7%) 0.19 
     Metformin 2 (3.3%) 130 (20%) 0.001 
     Sulphonylurea 1 (1.6%) 47 (7.5%) 0.086 
     Gliptin 0 (0.0%) 8 (1.3%) 0.37 
     Glitazone 0 (0.0%) 6 (1.0%) 0.44 
     Insulin 4 (6.6%) 85 (14%) 0.12 
Aortic cross-clamping time (min) 61 (46–71) 59 (47–70) 0.61 
CPB time (min) 80 (71–97) 80 (67–94) 0.80 
Operation length (min) 180 (150–220) 180 (160–210) 0.58 
Continuous variables are reported as median (25th – 75th percentiles). Values in parentheses are percentages. AMI: 
acute myocardial infarction; BMI: body mass index; CPB: cardiopulmonary bypass; eGFR: estimated glomerular fil-
tration rate using modification of diet in renal disease formula; GP: glycoprotein; IABP: intra-aortic balloon pump; 
INR: international normalized ratio; LMWH: low molecular weight heparin; PPS: postopercardiotomy syndrome.  
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Table 3. Postoperative characteristics after isolated CABG in patients with and without PPS. 
Modified from the original publication I, Table 2.  
The Cox regression multivariable model identified the use of 1 or more red blood cell 
units as an independent predictor of PPS (HR 1.9, 95% CI 1.1–3.2, p=0.017). Diabetes 
was detected to be an independent protective factor (HR 0.32, 95% CI 0.15–0.71, 
p=0.005).  
The relapse of PPS occurred in 23 of 61 (38%) PPS patients. PPS patients developing 
relapse were more obese (BMI 29 vs. 26, p=0.024) and had significantly shorter in-hos-
pital stay after the index surgery (7.0 vs. 8.0 days, p=0.017) when compared to PPS pa-
tients without relapse. No significant differences in the first-line medications for PPS 
were detected between patients with relapsed and non-relapsed PPS. Although not reach-
ing statistical significance, emergency operations (22% vs. 5.3%, p=0.050), NSAIDs as 
first-line medication for PPS (35% vs. 16%, p=0.087), and longer delay between the index 
operation and PPS onset (34 vs. 15 days, p=0.094) had a nonsignificant trend towards 
higher occurrence of PPS relapses. 
First-line medical treatment for PPS was glucocorticoids in 43%, NSAIDs in 23%, and 
colchicine in 15% of patients. PPS required the evacuation of pleural effusion in 13 (22%) 
patients and the evacuation of pericardial effusion in 3 (4.9%) patients. One patient 
(1.6%) developed cardiac tamponade due to PPS. No differences in the mortality rates 
were detected between patients with and without PPS. 
 PPS 
N=61 
No-PPS 
N=627 
P-value 
IABP 5 (8.2%) 47 (7.5%) 0.85 
Atrial fibrillation 11 (18%) 140 (23%) 0.41 
Stroke or transient ischemic attack 1 (1.6%) 29 (4.6%) 0.28 
Pneumonia 3 (5.7%) 19 (3.4%) 0.39 
Mediastinitis 1 (1.9%) 7 (1.2%) 0.69 
Red blood cell    
     ≥1 units used 37 (61%) 270 (43%) 0.008 
     Abnormal use (1-2 units) 19 (31%) 120 (19%) 0.019 
     Major use (>2 units) 18 (30%) 150 (24%) 0.36 
Fresh frozen plasma    
     ≥1 units used 11 (18%) 99 (16%) 0.61 
     Abnormal use (1-4 units) 11 (18%) 88 (14%) 0.40 
     Major use (>4 units) 0 (0.0%) 11 (1.8%) 0.30 
Platelets    
     ≥1 units used 7 (12%) 70 (11%) 0.95 
     Abnormal use (1-8 units) 7 (12%) 56 (8.9%) 0.51 
     Major use (>8 units) 0 (0.0%) 14 (2.2%) 0.24 
Bleeding (ml) 980 (670–1300) 830 (620–1200) 0.099 
Resternotomy for bleeding 4 (6.6%) 58 (9.3%) 0.48 
Surgical bleeding 5 (8.2%) 25 (4.0%) 0.12 
ICU stay (days) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.89 
In-hospital stay (days) 7.0 (6.0–8.0) 7.0 (5.0–8.0) 0.36 
Continuous variables are reported as median (25th – 75th percentiles). Values in parentheses are percentages. IABP: 
intra-aortic balloon pump; ICU: intensive care unit; PPS: postopericardiotomy syndrome; Surgical bleeding: a sig-
nificant bleeding from any anastomosis, graft, or vessel in the surgical field (pericardial artery, mammary vessels, 
Keynes' veins). 
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5.2 The impact of age and sex on the occurrence of PPS admissions 
(study II) 
During the study period of the study II, PPS was the primary cause of 760 hospital 
admissions. Most of the patients with PPS were male (67.8%). The median age of 
PPS patients was 63 (56–71) years, and the number of PPS patients increased by 
an estimated 82% (95% CI 66–98%) with every 10-year increment in age. Women 
with PPS were slightly older compared to men (63.4±11.6 vs. 61.1±11.3 years, 
p=0.007) and the number of female PPS patients increased steadily from 20 to 79 
years of age, whereas the number of male PPS patients increased more steeply 
from 40 to 60–70 years. The age distribution of PPS patients divided by sex is 
detailed in Figure 5. The median length of hospital stay was 6 (4–8) days, and 
17.3% of PPS patients had two or more admissions due to the syndrome. 
 
Figure 5. The age distribution of PPS patients divided by sex. From the original publication II, 
Figure 1B. PPS: postpericardiotomy syndrome. 
The total standardized incidence rate of PPS leading to hospital admission was 
2.22/100,000 person-years. The gender-adjusted incidence rate increased by an es-
timated 106% (95% CI 92–121%) with every 10-year increment in population age, 
and the rate and pattern of increase was similar for both sexes. The age-adjusted 
incidence rate of PPS was significantly higher in men compared to women (IRR 
2.49, 95% CI 2.05–3.02, p<0.0001). The gender-bias was not age-dependent 
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(p=0.49 for interaction). The incidence rate of PPS admissions is detailed in Figure 
6.  
 
Figure 6. Sex-specific incidence rate of PPS admissions in general population. From the original 
publication II, Figure 2B.  
Between 2002 and 2008, overall 22,373 cardiac surgery procedures in adults were 
identified in the participating hospitals in Finland. The median age of the patients 
was 67 (59–74) years and 73.4% of the patients were male. During the period in 
question, 550 admissions due to PPS were recorded resulting in an annual PPS rate 
of 2.46% (95% CI 2.25–2.67%) in the total study population. The rate of PPS was 
the highest in the youngest patients (11.5%) followed by a gradual decrease of 41% 
with every 10-year increment in age (RR 0.59, 95% CI 0.55–0.65, p<0.0001 per 
10-year increment in age). The occurrence of PPS in relation to cardiac surgeries 
is detailed in Figure 7. The rate of PPS in relation to the number of cardiac surger-
ies was significantly higher in women (2.99% vs. 2.28%; RR 1.78, 95% CI 1.45–
2.19, p<0.001). No significant interaction between sex and age was detected 
(p=0.87 for interaction). No significant annual changes were detected during the 
study period. 
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Figure 7. Sex-specific occurrence of PPS in relation to cardiac surgeries. From the original pub-
lication II, Figure 3B. PPS: postpericardiotomy syndrome. 
5.3 The impact of procedure type and mortality of PPS patients 
(Study III)  
The final patient cohort of the study III included 28,761 patients undergoing open-
heart surgery, from which 64.9% (n=18,679) underwent isolated CABG, 19.7% 
(n=5,674) underwent AVR ± CABG, 10.3% (n=2,964) underwent MVR ± CABG, 
and 5.0% (n=1,444) underwent ascending aortic surgery ± CABG and/or AVR. 
Within these patients, overall 493 PPS episodes were identified. PPS was the pri-
mary, secondary, or tertiary cause of admission in 99.4% of the PPS cases and 
0.6% were identified post-mortem. Median latency between the operation and PPS 
was 22 (12–49) days.  
The predictors of PPS are detailed in Table 4. In the univariable analysis, younger 
age was associated with higher PPS occurrence. No differences were detected in 
sex distribution and CCI between patients with and without PPS. The occurrence 
of PPS was significantly higher after AVR, MVR, and ascending aortic surgery 
when compared to CABG. Urgent or emergency procedures were also associated 
with higher PPS occurrence. No significant differences in the rate of PPS were 
detected in patients with and without resternotomy.  
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 Table 4. Predictors of PPS leading hospital admission or contributing to death. Modified from 
the original publication III, Table 2.  
The Cox regression multivariable model identified AVR, MVR, and ascending 
aortic surgery as independent predictors of higher PPS occurrence when compared 
to CABG. Urgent or emergency procedure also increased the risk, whereas an ad-
vanced age decreased the risk of PPS after the multivariable adjustment. The cu-
mulative rate of PPS stratified by operation type and the urgency of the procedure 
is detailed in Figure 8. The occurrence was equally higher in those undergoing 
AVR and MVR procedures when compared to those undergoing CABG, but 
clearly the highest occurrence appeared after aortic surgery. Concomitant CABG 
in valve and aortic procedures (HR 1.27, 95% CI 0.94–1.71, p=0.120), the use of 
LITA in CABG (HR 1.06, 95% CI 0.67–1.68, p=0.795), and the use of a mechan-
ical valve in AVR (HR 1.26, 95% CI 0.89–1.79, p=0.192) had no effect on the 
occurrence of PPS. 
 Univariable Analysis  Multivariable Analysis 
 HR (95% CI) P-Value  HR (95% CI) P-Value 
Age class  <0.001   0.006 
     18–40 years vs. ≥71 years 2.51 (1.56–4.04) <0.001  1.61 (0.98–2.64) 0.062 
     41–50 years vs. ≥71 years 1.93 (1.38–2.69) <0.001  1.77 (1.25–2.50) 0.001 
     51–70 years vs. ≥71 years 1.22 (1.00–1.48) 0.050  1.27 (1.03–1.55) 0.024 
Female sex 1.06 (0.87–1.29) 0.566  1.04 (0.84–1.27) 0.744 
Charlson Comorbidity Index (CCI)  0.739   0.833 
     Mild risk (CCI 1) vs. low risk (CCI 0) 1.00 (0.82–1.21) 0.965  0.93 (0.75–1.14) 0.698 
     Moderate risk (CCI 2) vs. low risk  
     (CCI 0) 0.86 (0.63–1.16) 0.308  0.89 (0.66–1.21) 0.618 
     High risk (CCI ≥ 3) vs. low risk (CCI 0) 0.91 (0.63–1.32) 0.620  1.00 (0.68–1.46) 0.992 
AVR (± CABG) vs. CABG 1.91 (1.54–2.36) <0.001  1.97 (1.58–2.46) <0.001 
MVR (± CABG) vs. CABG 1.76 (1.33–2.32) <0.001  1.62 (1.22–2.15) <0.001 
Aortic surgery (± AVR or CABG) vs. 
CABG 
3.49 (2.63–4.63) <0.001  3.06 (2.24–4.16) <0.001 
Urgent or emergency procedure 1.54 (1.16–2.05) 0.003  1.36 (1.00–1.83) 0.047 
Resternotomy 1.37 (0.92–2.05) 0.127  1.24 (0.82–1.88) 0.299 
AVR: aortic valve replacement; CABG: coronary artery bypass graft; CI: confidence interval; HR: hazard ratio; 
MVR: mitral valve replacement. 
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Figure 8. Cumulative PPS occurrence stratified by procedure type (A) and urgency of the proce-
dure (B). From the original publication III, Figures 2B and C. CABG: coronary artery bypass 
grafting. 
Overall 907 (3.2%) patients died within the first year after the surgery. The patients 
who died within the first 30 days after the surgery (244, 0.8%) were excluded from 
the mortality analyses to minimize the false-negative diagnoses of PPS. After the 
multivariable adjustment, PPS was associated with a 78% increase in the risk of 
death within the first year after the surgery. Survival after cardiac and ascending 
B
A
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aortic surgery in patients with and without PPS is detailed in Figure 9. Of the pa-
tients who died within the first year after the surgery, 10.5% had the diagnosis of 
PPS included in the death certificate. The mean delay between the initial PPS ad-
mission and death was 137±102 days. The causes of death in the patients who died 
within the first year after the surgery were similar between patients with and with-
out PPS, with ischemic heart disease (ICD-10 codes I20-I25) being the most com-
mon cause of death. 
 
Figure 9. Survival after cardiac and ascending aortic surgery in patients with and without PPS. 
From the original publication III, Figure 3. Patients who died within the first 30 days after the 
surgery were excluded. PPS: postpericardiotomy syndrome. 
5.4 Adverse events and mortality after moderate and severe PPS 
(study IV) 
In the study IV, a total of 75 (11.2%) patients developed PPS leading to delayed 
hospital discharge, readmission, or medical therapy due to the symptoms. The me-
dian latency between the operation and PPS onset was 16 (11–36) days. PPS re-
quired the evacuation of pericardial effusion in 15 (20.0%) patients, the evacuation 
of pleural effusion in 11 (14.7%) and led to cardiac tamponade in 7 (9.3%) patients. 
Thus, the incidences of moderate and severe PPS were 51 (7.6%) and 24 (3.6%), 
respectively.  
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The baseline characteristics and in-hospital events in patients with and without 
PPS are detailed in table 5. Patients with PPS were more often male, were more 
often diagnosed with postoperative pneumonia, and underwent more frequently a 
reoperation due to valve problem during the index hospitalization. Male patients 
with PPS were significantly younger compared to their female counterparts (69.0 
vs. 77.5 years, p=0.002), although no statistically significant interaction was de-
tected (sex*age groups interaction p=0.493). The multivariable model identified 
male sex (HR 1.78, 95% CI 1.08–2.96, p=0.025) and pneumonia during the index 
hospitalization (HR 2.73, 95% CI 1.38–5.43, p=0.004) as independent predictors 
of PPS. No significant differences between patients with moderate and severe PPS 
were detected except that patients with severe PPS presented more often a history 
of permanent AF (20.8% vs. 2.0%, p=0.001) and heavy alcohol consumption (33% 
vs. 5.3%, p=0.039).  
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Table 5. Baseline characteristics and in-hospital events after isolated AVR in patients with and 
without PPS. From the original publication IV, Table 1. 
No association was observed between PPS and all-cause mortality in the overall 
study cohort. However, severe PPS was associated with increased all-cause mor-
tality (unadjusted analysis: HR 1.91, 95% CI 1.01–3.62, p=0.046; EuroSCORE II 
 
PPS  
N=75 
No-PPS  
N=596 P-value 
Age 72.0 (59.5–77.0) 70.0 (60.0–77.0) 0.887 
Females 22 (29.3%) 272 (45.6%) 0.016 
Diabetes 8 (10.7%) 89 (15.0%) 0.420 
Dyslipidemia 42 (56.0%) 276 (46.5%) 0.134 
Hypertension 55 (73.3%) 403 (67.6%) 0.351 
Peripheral arterial disease 1 (1.3%) 19 (3.2%) 0.384 
Coronary artery disease 21 (28.0%) 144 (24.2%) 0.522 
Paroxysmal atrial fibrillation 7 (9.3%) 62 (10.4%) 0.578 
Permanent atrial fibrillation 6 (8.0%) 54 (9.1%) 0.991 
Chronic lung disease 10 (13.3%) 83 (13.9%) 0.969 
Active Smoking 7 (11.7%) 58 (12.7%) 0.796 
Active or ex-smoker 26 (44.1%) 171 (37.8%) 0.330 
Body mass index (kg/m2) 26.7 (24.7–29.5) 27.5 (24.3–30.9) 0.757 
Heavy alcohol consumption 4 (14.3%) 22 (9.0%) 0.392 
Previous stroke 4 (5.3%) 31 (5.2%) 0.987 
Previous myocardial infarction 6 (8.0%) 27 (4.5%) 0.359 
Previous percutaneous coronary interven-
tion 
8 (10.7%) 47 (7.9%) 0.495 
Previous cardiac surgery 2 (2.7%) 37 (6.2%) 0.317 
Active endocarditis 3 (4.0%) 28 (4.7%) 0.878 
Previous endocarditis 3 (4.0%) 17 (2.9%) 0.631 
Previous venous thromboembolism 2 (2.7%) 11 (1.8%) 0.496 
EuroSCORE II (%) 1.4 (0.9–2.1) 1.5 (0.9–2.4) 0.211 
Pulmonary artery hypertension:    
     Moderate to severe (systolic ≥31 mmHg) 13 (23.6%) 120 (29.0%) 0.500 
     Severe (systolic >55 mmHg) 3 (5.5%) 21 (5.1%) 0.754 
NYHA Class III or more 34 (45.3%) 313 (52.5%) 0.343 
Preoperative eGFR (mL/min/1.73 m²) 76.0±22.4 77.0±20.5 0.596 
Urgent, emergency or salvage procedure 3 (4.0%) 64 (10.7%) 0.105 
In-hospital events:    
     New-onset atrial fibrillation* 27 (43.5%) 192 (40.1%) 0.635 
     Deep wound infection 1 (1.3%) 4 (0.7%) 0.496 
     Mediastinitis 0 (0.0%) 5 (0.8%) 0.995 
     Pneumonia 11 (14.7%) 30 (5.0%) <0.001 
     Delayed ventilation 8 (10.8%) 70 (11.8%) 0.922 
     Acute de novo dialysis 1 (1.3%) 7 (1.2%) 0.778 
     Reoperation due to bleeding 9 (12.0%) 53 (8.9%) 0.295 
     Reoperation due to infection 1 (1.3%) 3 (0.5%) 0.340 
     Reoperation due to valve problem 2 (2.7%) 5 (0.8%) 0.045 
     Reoperation any 11 (14.7%) 59 (9.9%) 0.128 
Length of hospital stay (days) 8.0 (7.0–13.0) 8.0 (7.0–10.0) 0.197 
Continuous variables are reported as median (25th – 75th percentiles) or mean ± standard deviation (SD). Values in 
parentheses are percentages. EGFR: Estimated Glomerular Filtration Rate; EuroSCORE: European System for Car-
diac Operative Risk Evaluation; NYHA: New York Heart Association; PPS: postpericardiotomy syndrome. * Pa-
tients with preoperative paroxysmal or chronic atrial fibrillation excluded. 
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-adjusted analysis: HR 2.06, 95% CI 1.08–3.95, p=0.029), whereas patients with 
moderate PPS had similar survival that of the patients without PPS (unadjusted 
analysis: HR 0.67, 95% CI 0.36–1.27, p=0.220; EuroSCORE II -adjusted analysis: 
HR 0.78, 95% CI 0.41–1.49, p=0.454). Survival after isolated SAVR in patients 
with severe and moderate PPS and in patients without PPS is detailed in Figure 10. 
The difference in mortality of the patients with severe PPS appeared within the 
first 24 months after the surgery, and the median time from PPS to death was 460 
(83–1,300) days. Of the PPS patients who died within the first 24 months after the 
surgery (n=7), only one had PPS registered as the underlying cause of death and 
one as the intermediate cause of death. Pneumonia was registered as the immediate 
cause of death in half of the deaths, including the two deaths with PPS included in 
the death certificate.  
 
Figure 10. Survival after isolated SAVR in patients with moderate PPS (i.e., PPS not requiring 
the evacuation of pleural or pericardial effusion), patients with severe PPS (i.e., PPS requiring the 
evacuation of pleural or pericardial effusion), and patients without PPS. From the original publi-
cation IV, Figure 1. PPS: postpericardiotomy syndrome.  
The Cox regression univariable and multivariable models of the impact of PPS on 
adverse outcomes are detailed in Table 6. PPS had no significant impact on the 
adverse events. However, in both univariable and multivariable analyses there was 
a nonsignificant trend towards higher occurrence of new-onset AF after hospital 
discharge in patients with PPS. As illustrated in the Figure 11, this effect appeared 
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within one month after the surgery. No significant associations were detected be-
tween severe PPS and the higher occurrence of new-onset AF after hospital dis-
charge (HR 1.23, 95% CI 0.55–2.78, p=0.614), major stroke (HR 0.61, 95% CI 
0.09–4.44, p=0.629), stroke or TIA (HR 0.34, 95% CI 0.05–2.46, p=0.287), or 
major bleeding (HR 1.67, 95% CI 0.61–4.54, p=0.318). 
Table 6. The association of PPS and adverse outcomes after isolated SAVR. From the original 
publication IV, Table 2.  
 
Figure 11. Cumulative new-onset AF occurrence after hospital discharge in patients with and 
without PPS. From the original publication IV, Figure 3. AF: atrial fibrillation; PPS: postpericar-
diotomy syndrome. 
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Univariable analysis  
(PPS vs. no-PPS) 
 Multivariable analysis  
(PPS vs. no-PPS) 
HR (95% CI) P-value  HR (95% CI) P-value 
AF new onset 1.46 (0.97–2.19) 0.072  1.52 (0.95–2.45) 0.081 
Major stroke 0.45 (0.14–1.43) 0.174  0.46 (0.14–1.48) 0.526 
Stroke or TIA 0.60 (0.28–1.29) 0.188  0.63 (0.29–1.36) 0.432 
Major bleeding 0.95 (0.49–1.82) 0.868  1.03 (0.53–2.00) 0.901 
Death 0.99 (0.62–1.56) 0.989  1.13 (0.71–1.81) 0.361 
Death (alive after 30 
days) 
1.06 (0.65–1.73) 0.816  1.16 (0.71–1.91) 0.498 
AF: atrial fibrillation; CI: confidence interval; HR: hazard ratio; PPS: postpericardiotomy syndrome; TIA: transient 
ischemic attack.  
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6 DISCUSSION 
6.1 Incidence of PPS 
The main finding of the study I was that the incidence of PPS requiring medical 
attention was markedly lower compared to the incidences reported in recent clini-
cal trials (Imazio et al., 2010, 2014c). The result was later confirmed by study IV 
presenting a similar incidence in a different patient population, therefore ruling out 
the possible dependency on operation type and patient population. This finding 
suggests that majority of the PPS diagnoses included in the previous prospective 
studies are clinically irrelevant. 
In previous studies, the reported incidences have varied largely. This is most likely 
attributed to the lack of standardized diagnostic criteria until recent years (Adler et 
al., 2015). It may also refer to improvements in surgical and CPB techniques (e.g., 
smaller bypass circuit and avoidance of cardiotomy suckers) or changes in blood 
transfusion protocols and blood conservation strategies (Brand, 2000). However, 
these changes cannot explain the discrepancy between the studies during the last 
few decades.  
The standardized criteria for PPS were first published in the year 2015 (Adler et 
al., 2015). The criteria included significant changes compared to, for instance, the 
criteria proposed a few years earlier by Imazio et al. (Imazio et al., 2013c). The 
most important change was the removal of time limit from the criterion “fever 
without alternative causes”. Either a one-week or a 24-to-72-hour limit has been 
included in the diagnostic criteria in majority of the previous PPS studies, includ-
ing the recent COPPS trial (Imazio et al., 2010). In the COPPS-2 trial, however, 
the time limit was discarded (Imazio et al., 2014c). As can be observed in the sur-
vival plots of the COPPS and COPPS-2 trials, the inclusion of fever without a time 
limit results in a markedly higher incidence of PPS during the first days after the 
surgery. Another important change in the criteria recommended by the ESC guide-
line was the removal of the subcomponent “new or worsening” from the criterion 
“evidence of pericardial effusion” as well as from the criterion “pleural effusion 
with elevated CRP” (Adler et al., 2015).  
Fever early in the first postoperative week is virtually universal and in most cases 
remains for several days after the surgery (Livelli et al., 1978). It is usually caused 
by complement activation by CPB, early stasis atelectasis, and sensitivity reactions 
to drugs, transfusions, etc. (Gay, 2004). Pleural effusions are also a very common 
finding in the immediate postoperative period. The effusions may results from a 
variety of reasons related to the postoperative state, including atelectasis following 
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diaphragm dysfunction, hemorrhagic effusions following internal mammary artery 
harvesting, congestive heart failure, decreased chest wall compliance, pulmonary 
embolism, and pneumonia (Heidecker et al., 2006). According to Kaminsky et al., 
benign, surgery-related pleural effusions appear in 50% of the patients without PPS 
within the first 3 postoperative days (Kaminsky et al., 1982). Furthermore, small 
pericardial effusions during the time of discharge are also a common finding in 
patients without PPS (Heching et al., 2015). Considering the non-specificity of the 
diagnostic criteria, the explanation for the variability in the PPS incidences be-
tween previous studies is obvious. If one evaluates patients critically, most patients 
with cardiac trauma will meet the criteria for PPS. There is probably a continuum 
of responses to post-cardiac trauma ranging from mild fever and pericardial effu-
sion to a complete syndrome with intermittent fever, notable pericardial and/or 
pleural effusion, and pleuritic chest pain. 
In prospective trials, the detection of the benign, surgery-related findings is ex-
tremely sensitive because the follow-ups are mostly performed by PPS researchers. 
If the diagnostic criteria of the ESC guideline (Adler et al., 2015) are interpreted 
without criticism, this will result in an erroneously high incidence of PPS. Alt-
hough the criteria have been slightly different compared to the ones currently rec-
ommended, it is likely that a large part of the PPS diagnoses included in recent 
prospective trials are a result of the process ahead. This process also allows the 
diagnosing of asymptomatic pericardial and pleural effusions as PPS. This is pos-
sible even if the demonstration of inflammatory activity is required for the diag-
nosis because of the high frequency of fever and inflammatory marker rise during 
the postoperative era. It is questionable, whether a completely asymptomatic pa-
tient fulfills the classic definition of a postpericardiotomy “syndrome”. In the stud-
ies I and IV, these borderline cases were excluded due to the “clinically relevant” 
requirement, consequently leading to more usable risk factors in clinical practice.  
During the first decade after the discovering of PPS, patients were considered to 
have the disease if they were toxic and extremely enervated (Gore, 1960). In the 
past decades, however, the inclination of research has intentionally focused more 
and more on the sensitivity of the diagnosing of PPS (Imazio, 2012), also reflecting 
in the current guideline-recommended diagnostic criteria. It would presumably be 
more objective and specific to use the criteria introduced by Bunge et al.: at least 
two of the following: 1) new significant (>10 mm) pericardial effusion on echo-
cardiography, 2) new significant (above the highest level of the diaphragm) pleural 
effusion on chest x-ray, 3) unexplained fever >72 hours postoperatively, 4) pleu-
ritic chest pain, and 5) the presence of pericardial or pleural rubbing on physical 
examination (Bunge et al., 2014). This would likely discard the early post-trau-
matic effusions and enable the separation of the patients with the “classic” im-
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mune-mediated PPS. An even more sophisticated approach would be the one in-
troduced by De Scheerder et al. (De Scheerder et al., 1984, 1985b, 1986, 1991), 
including the concepts of “complete PPS” and “incomplete PPS”. The integration 
of the two aforementioned methods would allow the comparison of the most cer-
tain positive PPS patients with the most certain negative PPS patients. This is par-
ticularly important in the studies assessing the pathophysiological mechanisms of 
PPS, as it is uncertain whether the borderline PPS cases, especially the ones within 
the first few days after the surgery, share the same pathophysiological mechanism 
with the delayed, more certain cases. The hypothesis of two separate mechanisms 
is strengthened by the fact that although colchicine is effective in the prevention 
of PPS, it does not seem to be effective in the treatment of early postoperative 
pericardial effusions (Izadi Amoli et al., 2015; Meurin et al., 2015). 
6.2 Predictors of PPS 
The study I provided evidence that patients receiving red blood cells during the 
periprocedural period are at a higher risk for PPS. This effect did not appear to be 
connected to the number of red blood cell units transfused but to the overall use. 
Only two previous studies have investigated the frequency of blood product trans-
fusions in PPS patients (Maisch et al., 1979; van Osch et al., 2017a). In line with 
the study I results, in both studies, patients with PPS received more blood transfu-
sions during the periprocedural period, although not reaching statistical signifi-
cance in the study by van Osch et al. (transfusion of ≥ 2 units packed red cells 
23.1% vs. 17.0%, p=0.09). The effect of blood products may be associated either 
to the immunological aspects related to blood transfusions themselves or to the 
greater amount of perioperative bleeding. Transfusions of red blood cells stimulate 
IL-8 gene expression in neutrophils (Escobar et al., 2007) which may induce in-
flammation. Moreover, PPS has been previously associated with lower preopera-
tive IL-8 concentrations (Jaworska-Wilczyńska et al., 2014) and higher postoper-
ative IL-8 concentrations (Snefjellå et al., 2012) suggesting the participation of IL-
8 in the pathogenesis of PPS. On the other hand, pericardial bleeding is one of the 
previously presumed triggers for the syndrome (Imazio, 2012), and it also plays a 
central role in the recently established concept of retained blood syndrome (RBS) 
(Boyle et al., 2015). Besides, in the study I, there was a nonsignificant trend to-
wards more postoperative bleeding in patients with PPS. Therefore, the latter 
mechanism seems the most logical, although there is also a possibility of the two 
aforementioned mechanisms having a combined influence on the development of 
PPS.   
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In the study I, diabetes was found to be a protective factor for PPS. In the study 
IV, however, no significant association was detected, although a nonsignificant 
trend towards lower diabetes incidence within PPS patients was observable. The 
previous studies have reported inconsistent results concerning the effect of diabe-
tes. Contrary to the results of the study I, Imazio et al. reported a nonsignificant 
trend towards higher diabetes rate within PPS patients (28% vs. 23%, p=0.390). 
However, the data consisted of the patients of the COPPS trial that includes cardiac 
surgeries for any reason. Diabetes is a commonly known, extremely potent risk 
factor for numerous cardiac diseases, especially coronary artery disease (Oktay et 
al., 2018). Therefore, the evaluation of the influence of diabetes is complicated in 
settings including a wide variety of different procedure types. In a study by van 
Osch et al., a nonsignificant trend towards lower diabetes rate in PPS patients was 
noticeable (10.9% vs. 14.2%, p=0.79) (van Osch et al., 2017a). The study included 
only patients undergoing valve procedure with or without concomitant CABG, re-
sulting in a more restricted patient population compared to the COPPS trial. Over-
all, although needing further confirmation, it seems that while diabetes has some-
what of a protective influence against PPS in valve procedures, the protection is 
markedly more efficient in patients undergoing CABG.  
Diabetes and the obesity often related to it are known to lead to a proinflammatory 
state via numerous pathways as well as maladaptive immune responses (Oktay et 
al., 2018). It is therefore unlikely that diabetes itself would protect against PPS. 
After going through the diabetes medications, metformin appeared to be the pro-
tective factor for PPS, although all the other medications also had a nonsignificant 
trend towards lesser PPS frequency. According to previous studies, high-dose met-
formin potentiates lymphocyte-suppressing and systemic anti-inflammatory ef-
fects of simvastatin and fenofibrate in patients with early glucose metabolism ab-
normalities (Krysiak et al., 2012, 2013). Therefore, it seems probable that the pro-
tective effect of diabetes is mediated by metformin treatment, although further 
studies are needed to ensure the finding and possibly to evaluate the effect in pa-
tients without diabetes. Moreover, considering the existing literature, patients un-
dergoing CABG seem to be more sensitive for the possible PPS-protective effect 
of the drug.  
The study II showed that the rate of PPS in relation to the number of performed 
operations was significantly higher among women and younger patients. These 
results confirmed the previously reported associations between PPS and younger 
age (Drusin et al., 1965; Engle et al., 1980; Engle, 1982; Köhler et al., 2003) as 
well as PPS and female gender (Larson, 1957; Webber et al., 2001; Imazio et al., 
2011b). It has been previously suggested that the female predominance might re-
flect the different predisposition to autoimmune pathogenesis, as it is known that 
women are more susceptible to a variety of autoimmune diseases (Voskuhl, 2011) 
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possibly due to the effects of sex hormones on the immune system, genetic factors, 
and sex-specific behaviors and exposures (Gubbels Bupp, 2015). Even though the 
study II presented no statistically significant interaction between sex and age, the 
high incidence of PPS within women at the age group 40–49 years jumped out of 
the overall pattern (Figure 7). This could be explained by the hormonal changes 
related to menopause. In the study III, however, no significant association between 
PPS and sex was detected. The exclusion of complex combination procedures in 
the study III could possibly account for the discrepancy. A previous prospective 
study identifying female sex as an independent risk factor for PPS also included 
patients undergoing cardiac surgery for any reason (Imazio et al., 2011b). It is 
therefore possible that the effect of female sex is mediated by differences in pro-
cedure types, possibly by complex combination procedures in female aged 40–70 
years. Surprisingly, in the study IV, male sex was identified as an independent 
predictor of PPS. Male patients with PPS were, however, significantly younger 
compared to their female counterparts, even though the interaction analysis 
showed no significant interactions between age groups and sex. Regardless of the 
negative result, it is possible that the impact of male sex is indirect and due to 
differences in the age distributions of PPS patients in combination with the differ-
ences in procedure types. This hypothesis is strengthened by the fact that in the 
study IV only 1.0% of the female patients were 40–49 years of age which, accord-
ing to the study II, is the group with the highest difference in PPS occurrence be-
tween sexes. Overall, the effect of sex still remains somewhat unclear and needs 
further clarification. 
Although the studies II and III presented conflicting results of the effect of female 
sex, the results considering the effect of younger age were consistent in both stud-
ies. While the overall incidence of autoimmune diseases increases with age 
(Gubbels Bupp, 2015), different autoimmune diseases can affect a specific age 
group predominantly (Ramos-Casals et al., 2015) which could possibly explain the 
higher occurrence of PPS within younger patients. Considering the hypothesis of 
viral participation in the pathogenesis of PPS, aging leads to less frequent exposure 
to viral infections because of the alterations in the mode of life. Moreover, acquired 
protection due to the many years of exposure to viral illnesses may lead to the 
lesser PPS frequency with aging. It has been also discussed that the immunosenes-
cence related to aging might decrease the capability of mounting an immune re-
sponse against the intrapericardial trauma and possible exposure to viruses in the 
hospital (Engle, 1982). In particular, the aging-related activity reduction of T and 
B cells might play a central role in the aforementioned mechanism (Simon et al., 
2015). 
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The study III implicated that the incidence of PPS is markedly higher in those 
undergoing AVR, MVR, and aortic procedures when compared to patients under-
going CABG. Overall, previous studies have identified higher PPS occurrence af-
ter tetralogy of Fallot and VSD plus some other anomaly procedures compared to 
ASD, VSD only, TGA, and pulmonic stenosis procedures (Engle et al., 1980), 
valve replacement operations compared to CABG (De Scheerder et al., 1984, 
1991), and AVR compared to other open-heart operations (Miller et al., 1988; 
Gabaldo et al., 2019). Combination procedures have been also associated with the 
higher incidence of PPS, although it did not reach statistical significance in the 
multivariable analysis (Imazio et al., 2011b). In addition, mitral valve replacement 
has been associated with lower PPS occurrence (Miller et al., 1988). Nevertheless, 
a more recent study reported a significantly higher PPS frequency after mitral 
valve surgery compared to other valve procedures in the univariable analysis (van 
Osch et al., 2017a). Considering the results of the study III and the previous liter-
ature, more traumatic procedures seem to be related to the higher incidence of PPS. 
The effect is presumably mediated by more extensive pericardial trauma rather 
than myocardial trauma, as the degree of myocardial injury, at least assessed by 
circulating cardiac enzymes and sarcomeric proteins, seems to be unrelated to the 
occurrence of PPS (Nomura et al., 1994). These findings support the previously 
presumed mechanism of direct pericardial trauma acting as a trigger for the im-
mune-mediated process leading to PPS. That being said, it needs to be kept in mind 
that the syndrome can appear also after exploratory pericardiotomies in whom no 
further surgical procedures are attempted (Ito et al., 1958). According to previous 
literature, isolated valve procedures present lower postoperative bleeding within 
the first 12 hours after the operation compared to CABG procedure (Ranucci et al., 
2009). Therefore, pericardial bleeding alone is unlikely to be responsible for the 
higher occurrence of PPS after valve procedures, although it may still play a role 
in the pathophysiological mechanism of PPS. Besides the more extensive pericar-
dial trauma, a more complex procedure usually means longer time in CPB (Salis 
et al., 2008) and longer pericardial exposure to air and other unphysiological ma-
terials. These hypothetical causative factors should be investigated in further re-
search to evaluate their participation in the pathophysiology of PPS.  
Besides the pathophysiological considerations, the determination of the risk fac-
tors predisposing to PPS is crucial to provide effective targeting of possible pre-
ventive strategies minimizing the number of adverse events related to the methods 
used. According to the present results and previous literature, younger patients en-
tering valve or ascending aortic procedure and the patients receiving blood product 
transfusions due to the perioperative bleeding would be the best targets for the 
prophylactic methods. In addition, the methods might be considered in women 
aged 40–49 years. However, if the patient has metformin medication for diabetes 
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and is undergoing CABG, the risk of PPS is low and thus no prophylactic methods 
are needed. 
6.3 Etiology of PPS 
The results of the studies I–IV are consistent with the hypothesis of immune-me-
diated process being behind the pathogenesis of PPS. Furthermore, the higher oc-
currence of the syndrome after more extensive procedures and more periprocedural 
bleeding supports the view that pericardial trauma and pericardial bleeding act as 
triggers for the immune reaction. However, the role of perioperative and latent 
viral infections and perioperative exposure to air and other nonphysiological ma-
terials still remains obscure. The proposed pathogenesis of PPS, according to the 
present results and previous literature, is detailed in Figure 12. The pleuropericar-
dial trauma leads to the release of antigens, including most likely at least actin, 
myosin, troponin I and T, tropomyosin, and branched chain alpha-ketoacid dehy-
drogenase dihydrolipoyl transacylase (BCKD-E2) (Wehlou et al., 2009). The re-
action against the released antigens may be mediated by two possible mechanisms: 
1) the pericardium and pleura are immunologically privileged spaces, and once the 
antigens release, they become autoreactive, or 2) the exposure of the pericardium 
and pleura to exogenous factors, such as concurrent viral infections or air, lead to 
the denaturation of the released proteins so that they become “foreign” material 
and thus induce the production of autoantibodies. The production of the autoanti-
bodies leads to a hypersensitivity reaction mediated by either direct antibody-me-
diated (AHA) reaction, cell-mediated autoreactive reaction, or complement cas-
cade activation. This delayed hypersensitivity reaction involves the epicardial 
layer of the pericardium, often accompanied with the “neighbourhood” involve-
ment of the pleura even if the pleural space was not entered during the surgery. 
The early pericardial effusions, typically appearing within the first days after the 
surgery, are a result of pericardial bleeding and posttraumatic effusions. Thus, no 
immune-mediated reaction is required for their development. However, if the 
blood effusions retain, it may lead to clot formation releasing thrombin and fibrin. 
These products act as chemoattractants either strengthening or inducing the hyper-
sensitivity reaction via the increased release of inflammatory cytokines from the 
mesothelial cells of the pericardium and pleura. Blood product transfusions may 
also contribute to the chemotactic response via the stimulation of IL-8 gene ex-
pression in neutrophils.  
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Figure 12. Proposed pathogenesis of PPS. Artwork by Joonas Lehto. AHA: anti-heart antibody; 
NSAID: non-steroidal anti-inflammatory drug; PPS: postpericardiotomy syndrome.  
The pharmacological actions of the medical therapies of PPS, especially colchi-
cine, closely intertwine with the presumed pathophysiological mechanism of PPS. 
The main effects of the medical therapies are most likely mediated by two different 
pathways: 1) the inhibition of the immune response activation against autoantigens 
and 2) the inhibition of the chemoattraction induced by the clot formation products 
and possibly by blood product transfusions. Even though the exact mechanism of 
colchicine action is not fully understood, most of the effects on inflammatory cells 
appear to be related to its capacity to disrupt microtubules. This leads to the down-
regulation of multiple inflammatory pathways and the modulation of innate im-
munity. One of the main effects of colchicine is the reduction of neutrophil-medi-
ated immune reaction via, inter alia, the inhibition of neutrophil chemotaxis, adhe-
sion, mobilization, recruitment, and superoxide production. Other important ef-
fects include macrophage downregulation and thus the modulation of innate im-
mune response (Leung et al., 2015). The therapeutic and preventive effects of col-
chicine are largely related to its rapid redistribution to leukocytes, as the disruption 
of microtubules is dose-dependent (Molad, 2002).  
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6.4 Relapses of PPS 
In the study I, overall 38% of the PPS patients had a relapse defined by worsening 
of pericardial or pleural effusion while on medication or after the withdrawal of 
medication. In the study IV, the relapse rate was markedly lower (16%). PPS pa-
tients of the study IV were more often treated with glucocorticoids (64% vs. 43%) 
and less often with NSAIDs (5% vs. 23%). Therefore, the possible increased re-
currence rate related to glucocorticoid treatment (Artom et al., 2005; Imazio et al., 
2005a, 2005b, 2005c, 2013b; Adler et al., 2015) is unlikely to explain the differ-
ence between the studies. In previous studies, the recurrence rates have varied be-
tween 4% and 21% (Drusin et al., 1965; Nishimura et al., 1983; Imazio et al., 
2011b). The higher recurrence rate especially in the study I is most likely related 
to the fact that only more severe PPS cases, referring to the PPS cases requiring 
medical attention, were included. However, it does not explain the difference be-
tween the studies I and IV. It therefore appears that patients undergoing isolated 
AVR are at lower risk of PPS recurrences compared to CABG, most likely due to 
the numerous baseline differences between the populations.  
6.5 Prognosis of PPS 
Although PPS is known to cause prolonged hospital stay, readmissions, and inva-
sive interventions, the prognosis of the syndrome has been considered to be benign 
(Bucekova et al., 2012; Imazio et al., 2013d; Adler et al., 2015). However, this 
perception has been mainly based on clinical experience rather than adequate epi-
demiological studies. Only one previous study has evaluated the mortality of PPS 
patients (van Osch et al., 2017a). In the aforementioned study, patients with PPS 
represented an excellent 1-year prognosis (1-year mortality 4.2% vs. 5.5%, 
p=0.497). However, the study included only 119 patients with PPS and fewer pa-
tients with complete follow-up for death, of whom only 4 died within the first year 
after the surgery (expected value 5). Therefore, no clear conclusions can be driven 
from these results.  
The study III provided evidence that PPS is associated with a >1.7-fold increase in 
the risk of death within the first year after the index surgery. None of the causes of 
death was overrepresented in patients with PPS who died within the first year after 
the surgery. Instead, the patients had an equal rise in all causes of death which from 
ischemic heart disease was the most common. The study IV further evaluated the 
reasons for the higher mortality. Severe PPS was found to be associated with a 
twofold all-cause mortality while moderate PPS presented similar survival to that 
of patients without PPS (Figure 10). Of the severe PPS patients who died within 
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the first 24 months after the surgery (n=7), only one had PPS registered as the 
underlying cause of death and one as the intermediate cause of death. Again, the 
underlying cause of death was often registered as atherosclerotic heart disease or 
aortic valve stenosis. Pneumonia was registered as the immediate cause of death 
in half of the deaths, including the two deaths with PPS included in the death cer-
tificate. In both the study III and IV, the incremental deaths appeared with a delay 
of several months after the syndrome. Therefore, a direct link to the hemodynamic 
problems caused by the syndrome was unlikely. 
According to the results of the study IV, the increased mortality associated with 
severe PPS is unlikely to be related to new-onset AF, cerebrovascular events, or 
major bleeds. Considering the safety of the medical treatment for PPS, colchicine 
has no significant effect on the overall mortality (Imazio et al., 2014c, 2014a). The 
effect of short-term corticosteroids on mortality in the presence of heart disease is 
poorly documented. Although long-term use of high-dose corticosteroids is asso-
ciated with an increased risk of cardiovascular disease and mortality (Wei et al., 
2004), the effect appears within several years rather than months (Ajeganova et 
al., 2014) and in high cumulative exposure (Davis et al., 2007; del Rincón et al., 
2014). The use of NSAIDs is also associated with myocardial infarctions and 
higher mortality attributable to coronary heart disease (Coxib and traditional 
NSAID Trialists’ (CNT) Collaboration et al., 2013), but the effect is insignificant 
in therapies with a length of <1 month (García Rodríguez et al., 2008), which is 
typical in the treatment of PPS. Therefore, the medical therapies for PPS are also 
unlikely to be responsible for the higher mortality.  
Given the results of the studies III and IV, the higher mortality is most likely 
caused by the incremental disease burden of PPS and its sequelae, and especially 
the required interventions. It seems unlikely that PPS itself is the cause of the in-
cremental deaths after cardiac surgery. Instead, PPS is likely to complicate previ-
ously weak and vulnerable patients, thus increasing mortality with a delay. How-
ever, even though the relationship with the underlying immunological changes 
caused by or resulting in PPS seems unlikely, further studies are needed to rule it 
out completely.  
The association with an increased mortality supports the use of relatively aggres-
sive prophylactic methods to prevent PPS. Therefore, for example, the increased 
risk of gastrointestinal adverse effects of colchicine should not be interpreted as an 
insuperable obstacle for the preventive use of the drug. According to the present 
results, the one-month colchicine prophylaxis, also recommended for considera-
tion in the ESC Guideline (Adler et al., 2015) (class IIaA recommendation), should 
be adopted in the current clinical practice. If necessary, the preventive treatment 
could be targeted to the patients in the highest risk of developing PPS, as detailed 
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above. It needs to be taken into consideration, however, that the evidence of 
whether the preventive therapies diminish the risk of mortality is lacking (Imazio 
et al., 2014c). Nevertheless, the adoption of the prophylactic colchicine treatment 
would also allow the execution of large epidemiological studies evaluating the ef-
fect of the drug on mortality in long-term follow-up.  
Considering the other complications related to PPS, only one patient had PPS lead-
ing to clinical cardiac tamponade in the study I. In the study IV, however, alto-
gether 7 patients had PPS leading to tamponade resulting in a notably higher inci-
dence of tamponade compared to the study I (9.3% vs. 1.6%). PPS required the 
evacuation of pericardial effusion in 20.0% and 4.9% and the evacuation of pleural 
effusion in 14.7% and 22% of the PPS patients in the studies IV and I, respectively. 
It therefore appears that although AVR patients experience less PPS recurrences, 
the syndrome itself is more severe compared to after CABG procedure. This con-
clusion is supported by the study by van Osch et al. including patients undergoing 
valve procedures, in which PPS patients had an over 15-fold risk of reoperation 
for all-cause tamponade within the first year after the surgery (20.9% vs. 2.5%). In 
the study by Imazio et al., the incidence of PPS-related tamponade was 1.9% after 
cardiac surgery for any reason (Imazio et al., 2011b). However, half of the patients 
were receiving prophylactic colchicine potentially affecting the number of adverse 
events related to PPS. Delayed cardiac tamponade, referring to tamponade after 
the first postoperative week, has been reported to occur in 0.8–1.3% of PPS pa-
tients (Bortolotti et al., 1981; Ofori-Krakye et al., 1981).  
The study IV provided evidence that PPS is not associated with major stroke, 
stroke or TIA, or major bleeding episodes. Importantly, PPS did not have a signif-
icant impact on the occurrence of new-onset AF during long-term follow-up. How-
ever, patients with PPS had somewhat (although nonsignificant) higher occurrence 
of new-onset AF within the first month after the surgery (Figure 11). It is therefore 
possible that the pericardial irritation caused by PPS provokes AF paroxysms dur-
ing the first months after the surgery, but the effect is most likely transient. This 
result is consistent with the few previous studies assessing the impact of PPS on 
new-onset AF (Papp et al., 1956; van Osch et al., 2017a). Only one study has re-
ported a significant association between PPS and POAF (Sevuk et al., 2016a), but 
because of the multiple baseline differences between the study groups and the 
strikingly high PPS occurrence, these results cannot be considered reliable. The 
previous knowledge concerning other adverse events related to PPS is limited to a 
single study (van Osch et al., 2017a). In line with the study IV results, van Osch 
et al. found no significant associations between PPS and stroke or reoperation for 
surgical bleeding. Also, PPS had no significant impact on the incidence of myo-
cardial infarctions or readmissions (any reason) within one year or the incidence 
of pleural punctures performed within one month after the surgery.  
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The study IV introduced the concepts of moderate and severe PPS. The higher 
mortality in severe PPS patients supports the view that severe PPS should be con-
sidered as an end point in the future clinical trials. In addition, the classification 
into the subgroups might be useful in the treatment of PPS patients, as it reflects 
the prognosis of the patients. Patients with moderate PPS can be safely treated with 
symptomatic therapies in the outpatient clinics, while severe PPS patients require 
more intensive follow-up and treatment.  
6.6 Strengths and limitations 
The present research offers novel findings concerning the risk factors and progno-
sis of PPS. All of the studies only include the PPS cases severe enough to require 
medical attention making the results more clinically relevant and usable in prac-
tice. The study I includes numerous unexplored risk factors for PPS and factors 
that have only been investigated in small studies. The studies II and III are the 
largest studies concerning PPS to date and the first studies to offer epidemiological 
nationwide data. Moreover, the study III is the first study large enough to provide 
adequate evidence concerning the prognosis of PPS. In addition, before the study 
IV, the possible adverse events related to PPS have been only investigated in single 
studies.  
The main limitation of the studies I–IV, apart from the prospective CAREBANK 
data included in the study IV, is the retrospective nature of the data. The small size 
of the studies I and IV is another limitation. Therefore, the results should be con-
sidered as hypothesis-generating except for mortality increase seen in both nation-
wide material and multicenter setting. Also, all tests leading to the diagnosis of 
PPS (e.g., chest x-ray and echocardiography) were not performed in every patient, 
so the underdiagnosing of asymptomatic PPS is conceivable. Nevertheless, the 
tests were performed as clinically indicated, reflecting the “real world” feature of 
the studies.  
Although the studies II and III included all hospitals that perform cardiac opera-
tions in Finland, in addition to all central hospitals and largest regional hospital 
nationwide, it is possible that some of the PPS patients were treated in the smaller 
regional hospital not included in the data collection. Also, only patients admitted 
to a hospital were included. Because patients with mild symptoms can be treated 
at outpatient clinics, they were not included in these studies. Besides, there is also 
a possibility of underdiagnosing in the presence of one or few mild PPS-related 
symptoms, when the physician treats the symptoms (e.g., by anti-inflammatory 
medications), but the exact PPS diagnosis is not set. Therefore, the results can be 
directly applied only to PPS cases severe enough to result in hospital admission. 
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In both the studies II and III, the treating physicians made the diagnoses. Ideally, 
this would mean better differential diagnostic procedures and more certain diag-
noses. However, the lack of nationwide criteria was unavoidable, because there 
were no standardized criteria for the syndrome until 2015 (Adler et al., 2015). It is 
also possible that the assignment of PPS diagnosis became disturbed in the pres-
ence of other more dominant conditions, such as stroke or death. This would, how-
ever, only further strengthen the conclusion of increased mortality observed in the 
study III.  
6.7 Future aspects 
In the studies presented, we have explored the incidence, risk factors, and progno-
sis of medically relevant PPS using multiple research methods and populations. 
We have also brought out the problems in the currently recommended diagnostic 
criteria and recent prospective trials. As the etiology of PPS still remains uncertain, 
there is a need for further studies concentrating especially to the immunopatholog-
ical mechanisms leading to the onset of the syndrome. However, these investiga-
tions should be focused on comparing the most certain or severe PPS cases to the 
ones without any significant signs of the syndrome. This would allow the more 
specific investigation of the “classic” immune-mediated PPS and hence the path-
ophysiology could be eventually unraveled. To achieve this and to reduce the het-
erogeneity between future studies, the currently recommended diagnostic criteria 
for PPS should be reconsidered. Moreover, future clinical trials assessing the 
prophylactic methods to prevent PPS should include severe PPS, referring to PPS 
requiring invasive interventions, as a separate endpoint to better evaluate the prog-
nostic value of, i.e., the prophylactic administration of colchicine. This more prag-
matic approach enables the improvement of patient care and recovery and the iden-
tification and avoidance of the factors leading to higher mortality. 
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7 CONCLUSIONS 
The following conclusions may be drawn from the present investigation: 
PPS has no significant impact on the occurrence of new-onset AF, cerebrovascular 
events, or major bleedings. Nevertheless, severe PPS, defined as PPS requiring the 
evacuation of pericardial or pleural effusion, is associated with higher all-cause 
mortality within the first 24 months after the surgery. These patients are in need of 
more intensive follow-up and treatment. 
The incidence of PPS requiring medical attention is markedly lower compared to 
the incidences in earlier reports implicating that most of the diagnoses included 
especially in the recent prospective trials are clinically irrelevant. Therefore, the 
currently recommended diagnostic criteria need to be reconsidered and clarified. 
PPS is more common in younger patients, in patients receiving blood product 
transfusions due to the perioperative bleeding, and after more traumatic proce-
dures. These patients would be the best targets for the prophylactic methods 
against the syndrome. In addition, female sex is associated with higher PPS occur-
rence, although the effect seems to be procedure- and/or age-dependent. Diabetes, 
potentially mediated by the metformin treatment, is a protective factor against PPS 
especially in CABG procedures reducing the need for the disease prophylaxis.  
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